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Cardiovascular diseases are the leading cause of death globally and continue to be 
a growing health concern. The currently available therapies are not suitable or effective 
for all patients, which has prompted investigation into stem cell-based therapies for 
vascular regeneration and ischemic repair. Clinical trials using stem cell therapy have 
shown promising outcomes for patients with cardiovascular diseases.  However, the 
mechanisms of repair, and the contribution of stem cells to wound healing, are poorly 
understood. The objective of this dissertation is to evaluate the use of bone marrow-
derived mesenchymal stem cells (MSCs) delivered within a PEGylated fibrin gel for 
revascularization therapies. Demonstrated in this dissertation is the design of nanoparticle 
contrast agents which are capable of labeling and tracking stem cells and infiltrating 
macrophages in vivo. In addition, the effect of hypoxia on MSC function and the resulting 
interaction with macrophages was studied. Hypoxia was shown to modulate MSCs to 
have pro-regenerative and angiogenic-promoting properties, which subsequently affected 
the interaction with macrophages. Lastly, functional recovery and vascular regeneration 
in an in vivo ischemia model were shown to be enhanced in response to MSCs delivered 
within PEGylated fibrin gels. The results of this work provide insights into the 
mechanisms of stem cell therapy in combination with PEGylated fibrin matrices and can 
contribute to the advancement of the field of regenerative medicine.  
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 1 
Chapter 1: Introduction 
1.1 BACKGROUND AND MOTIVATION 
1.1.1 Cardiovascular diseases 
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood 
vessels and are the number one cause of death globally.
1
 An estimated 17.3 million 
people died from CVDs in 2008 (30% of all global deaths),
2
 and this number is expected 
to reach 23.3 million by 2030
2,3
. Common causes and risk factors for CVDs include 
diabetes, smoking, high cholesterol, obesity, and high blood pressure.
2
 CVDs are most 
commonly the result of atherosclerotic plaque buildup, leading to narrowing of the 
arteries and ischemia of the downstream tissue.
4
 CVDs include coronary heart disease, 
cerebrovascular disease, and peripheral artery disease.  
Peripheral artery disease (PAD), which is characterized by reduced blood flow in 
the extremities, affects 8-10 million people in the United States and is characterized by 
intermittent claudication, leg pain and muscle weakness, and foot ulcers.
5
 The disease can 
further progress to critical limb ischemia, in which the resting metabolic needs of the 
limb are not met by the available blood supply.
5
 If the blockages are left untreated, tissue 
infection or death, and possibly amputation, could occur. Current therapies include 
antiplatelet medication, angioplasty, and bypass grafting, all of which aim to promote 
revascularization of the ischemic tissue. However, approximately 50% of patients with 
critical limb ischemia are not eligible for revascularization procedures
6
 and thus will 
either die or require amputation of the affected limb within one year of diagnosis
7
. Of 
those patients who undergo revascularization procedures, about 50% will require an 
additional surgery within 6 months and <50% will achieve complete wound healing at 3 
months.
8
 In addition, limb amputation (30% of cases) and death are still frequent 
 2 
complications.
9
 As a result, it is imperative to explore new revascularization strategies for 
PAD. Regenerative medicine and cell-based therapies are widely being investigated as 
alternative strategies for the currently available revascularization techniques.  In 
particular, bone marrow-derived mesenchymal stem cells have shown great promise in 
preclinical and clinical trials for patients with PAD.
9
 
1.1.2 Stem cell therapy and biomaterial matrices for vascular repair 
Mesenchymal stem cells (MSCs) are an adult stem cell population found within 
multiple regions of the body (including the bone marrow and adipose, placental, and 
vascular tissues
1,10
) and which can terminally differentiate into mesodermal lineages. 
MSCs are typically positive for CD44, CD90, and CD105 and negative for CD45 
(hematopoietic), CD31 (endothelial) and CD11b (macrophage) markers.
1
 Transplanted 
MSCs have also been demonstrated to differentiate into bone marrow stromal cells, 
pericytes, myofibroblasts, and endothelial cells.
10
 MSCs do not have any MHC class II 
surface markers, essentially rendering them invisible to the host’s immune system.11 
Thus, MSCs are an ideal candidate cell type for therapeutic revascularization, and many 
research groups have demonstrated blood vessel formation and increased reperfusion of 
ischemic areas following delivery of MSCs or other stem cells,
12-14
 either through direct 
cell differentiation or paracrine effects
1,14,15
. In addition, as shown in Table 1.1, clinical 
trials involving therapeutic delivery of MSCs to ischemic skeletal muscle have 
demonstrated improved muscle function and vascular regeneration.
9
 While MSCs have 
the potential to differentiate to endothelial and skeletal muscle cell types, the low MSC 
survival rate following delivery in vivo suggest that delivered cells may play a primarily 
paracrine role in healing.
16
 MSCs have been shown to secrete factors which are pro-
angiogenic and promote wound healing (e.g. vascular endothelial growth factor (VEGF), 
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fibroblast growth factor (FGF), angiopoietin, platelet-derived growth factor (PDGF), 
stromal cell-derived factor (SDF)-1, interleukin-6, matrix metalloproteinase (MMP)-9, 
transforming growth factor (TGF)-β, macrophage inflammatory protein (MIP), and 
monocyte chemoattractant protein (MCP)) through interactions with other cell types, 
including endothelial cells and macrophages.
1,14,15,17
 In addition, secretion of these factors 
by MSCs has been shown to be upregulated under hypoxic conditions.
18,19
 However, the 
mechanisms by which MSCs contribute to vascular repair are poorly understood, and the 
advancement of stem cell therapies and clinical trials are hindered by the limited 
information concerning cell function in vivo and the inability to monitor the cells 
following delivery. 
Biomaterial delivery systems can assist in cell-based revascularization therapies 
by increasing the rate of cell retention at the delivery site and altering the cellular 
microenvironment, leading to changes in cell function. Fibrin-based matrices are an 
attractive biomatrix material for wound healing purposes because fibrin is biocompatible, 
has high affinity to various biological surfaces, supports angiogenesis and tissue repair, 
contains sites for cellular binding, and is FDA approved.
20
 Fibrin is also a natural 
component of the wound healing response and is formed naturally in the body after 
thrombin cleavage of fibrinopeptide A from fibrinogen Aα.21 Fibrin gels can be made as 
an injectable system,
22
 and the rate of fibrin matrix degradation can be controlled by 
cross-linking with synthetic polymers,
20
 such as polyethylene glycol (PEG)
23-25
. 
PEGylation also serves to overcome the limitation of poor mechanical properties of the 
gel.
26,27
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1.1.3 Cell tracking and vascular imaging 
1.1.3.1 Contrast agents for cell tracking 
Tracking cell fate in vivo is critical in order to better understand the biological 
mechanisms underlying disease states and potential therapies. Monitoring cells following 
in vivo delivery would provide important information concerning cell persistence and 
engraftment, cell localization, cell survival, and the participation and role of administered 
cells in wound healing processes. Conventional methods for assessing these mechanisms 
rely on postmortem histology,
28
 which only offers endpoint measurements and requires a 
large number of animals to be sacrificed in order to produce statistically significant 
results. A more ideal cell tracking method would involve noninvasive longitudinal 
imaging to monitor cells. Towards this end, many contrast agents are available and 
currently being investigated to label cells for longitudinal imaging purposes. The ideal 
contrast agent should be safe and biocompatible, not affect cell function, allow for 
longitudinal imaging with high sensitivity and cell quantification, have minimal decrease 
in signal over time (due to contrast dilution as a result of cell division), and not be 
transferred to non-stem cells in vivo.
29,30
  
Some of the most common labeling techniques include radionuclides, reporter 
genes, fluorescent probes, and nanoparticles. Radionuclides are radiolabeled markers and 
include 
111
indium oxine, 18F-flurodeoxygluocse (FDG), and 
99
mtechnetrium 
exametazine. Radionuclide contrast agents are commonly used for single-photon 
emission computed tomography (SPECT) imaging. While SPECT imaging can provide 
quantitative and spatial information concerning cell distribution following administration, 
the short half-lives of radionuclides limit long-term imaging.
31
 In fact, the longest 
reported imaging time was 120 hours following delivery of cells labeled with 
111
In.
31
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Thus, only early biodistribution following cell delivery can be observed
32
 and long-term 
monitoring is not capable with radionuclide labeling.  
Reporter gene labeling involves genetically manipulating the cell by introducing a 
reporter gene construct. A reporter protein is produced and detected by an imaging probe 
introduced into the subject, resulting in production of a signal which is detected by an 
imaging modality, such as positron emission tomography (PET) or SPECT. Reporter 
gene labeling allows for stable imaging of cell migration, proliferation, and viability, but 
cell function can be compromised as a result of transfection.
33,34
 In addition, nuclear 
medicine imaging modalities (PET and SPECT) can be harmful to patients because of the 
ionizing radiation.  
Fluorescent probes are compounds which are excited to a higher energy state by 
light, and then re-emit energy in the form of light as a result of returning to the ground 
state. They can be imaged using optical imaging techniques with high sensitivity and 
resolution, but suffer from loss of signal over time due to photobleaching and limited 
penetration depth.
31,33
 
Nanoparticles (such as quantum dots, iron oxide nanoparticles, and plasmonic 
noble metal nanoparticles (gold and silver)) can be optimized to promote cellular uptake 
and allow for long term monitoring.
35-39
 Nanoparticles can be imaged with a variety of 
imaging modalities, including magnetic resonance imaging, radionuclide imaging (PET 
and SPECT), optical imaging, and hybrid imaging (photoacoustic). Quantum dots are 
semiconductor nanoparticles (usually 2-10 nm) which can be excited by a wide range of 
wavelengths, exhibit size-dependent tunable emission, and are relatively photostable.
40-43
 
However, most of the currently available quantum dots contain toxic core substances,
31,44
 
and need to be tuned to emit and excite within the near-infrared region to allow for deep 
tissue imaging.
31
 Iron oxide nanoparticles are commonly used as magnetic resonance 
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imaging contrast agents. Superparamagnetic iron oxide (SPIO) nanoparticles consist of 
an iron oxide core (as small as 5 nm
45,46
) and are FDA approved. Polymers such as 
dextran, carboxydextran, or polylysine are often used to coat SPIO nanoparticles in order 
to prevent nanoparticle aggregation
45-47
 and increase cell labeling efficiency
46,47
. Gold 
nanoparticles can be made in a variety of sizes and shapes (e.g. spheres, rods, shells, and 
cages), and these intrinsic properties determine the wavelengths at which gold 
nanoparticles maximally absorb and resonantly scatter light.
48-50
 In addition, the core of 
gold nanoparticles is inert and non-toxic to cells,
48,51
 and various surface coatings can be 
conjugated to the gold surface via thiol or amine moieties, which have well defined 
surface chemistries with gold
47,48
. Gold nanoparticles are commonly used as contrast 
agents for cell labeling in applications related to cancer imaging, diagnosis, and 
therapy.
52-54
 However, the use of gold nanoparticles is also being extended to stem cell 
labeling and in vivo tracking. Gold nanoparticles exhibit surface plasmon resonance, 
which contributes to their superior optical absorption properties,
55,56
 making them ideal 
contrast agents for photoacoustic imaging. 
1.1.3.2 Photoacoustic imaging 
Photoacoustic imaging is based on the photoacoustic effect, in which light energy 
is transformed into sound energy. Photoacoustic imaging involves irradiating a biological 
tissue source of interest with a nanosecond laser pulse.  The photon energy is absorbed by 
the tissue, leading to a temporary temperature increase and thermoelastic expansion of 
the tissue.
57
 Acoustic waves are then emitted and detected using an ultrasound transducer. 
Due to the fact that an ultrasound transducer is used to collect photoacoustic signals, 
photoacoustic imaging can easily be combined with ultrasound imaging in order to 
provide both functional and structural information, respectively. As a result, 
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photoacoustic imaging combines the benefits of ultrasound (penetration depth) with 
optical imaging (molecular specificity).
58,59
 In order to efficiently generate photoacoustic 
signals, the laser pulse needs to be short enough to satisfy both thermal and stress 
confinement conditions.
57,59
 Under these conditions, the photoacoustic signal is linearly 
proportional to the laser fluence, optical absorption coefficient of the material, and the 
Grüneisen coefficient.
57
 Thus, contrast in photoacoustic imaging is largely dependent 
upon the optical absorption coefficient. The optical absorption properties of various 
tissues are shown in Figure 1.1. The range of wavelengths from 700-1000 nm is known 
as the tissue optical window, in which absorption from endogenous tissue is dramatically 
decreased and light is able to penetrate deeply (several centimeters) into biological 
tissue.
59
 As a result, designing contrast agents, such as gold nanoparticles, which have 
high optical absorption properties within the tissue optical window is advantageous. 
1.1.4 The role of hypoxia in wound healing and vascular regeneration 
The percentage of stem cell death following therapeutic delivery is quite 
significant,
16,60
 due primarily to the harsh, ischemic environment at the delivery site. This 
means that studies tracking cell fate using biomedical imaging may actually be 
monitoring cells which are primarily dead. However, hypoxia-induced cell death can be 
mitigated using cell priming techniques and altering the cellular microenvironment.
18
 In 
order to optimize such techniques, there is a need to understand the response of stem cells 
to hypoxia, both in vitro and in vivo, and the implications of hypoxia on stem cell 
function.  
Bone marrow-derived mesenchymal stem cells reside in a hypoxic niche (2-6% 
oxygen) within the bone marrow cavity.
61-64
 Under ischemic conditions (1-2% oxygen), 
MSCs have been shown to produce improved angiogenic responses.
18,19,62,65,66
 MSCs 
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cultured under hypoxia also maintain a more multipotent, undifferentiated state.
67
 In 
order to adapt to low oxygen tensions, stem cells upregulate the production of hypoxia 
inducible factor (HIF).
19
 HIFs are transcription factors which activate pathways that are 
pro-angiogenic and anti-apoptotic. Under normoxic (20% oxygen) conditions, HIF-1α is 
hydroxylated at proline residues, labeling them for rapid degradation.
19
 However, when 
oxygen tension is low, HIF-1α is hydroxylated and is thus stabilized, leading to the 
modulation of up to 200 genes involved in processes including angiogenesis, production 
of erythropoietin, cell proliferation, and apoptosis.
19
 Furthermore, the degree of HIF-1 
stabilization is inversely proportional to the oxygen concentration.
68
 Thus, in order to 
improve the survival of stem cells following delivery within an ischemic site, many have 
implemented hypoxic pre-conditioning methods so as to protect the transplanted cells 
during the initial critical period after transplantation.
18
 Hypoxic pre-conditioned stem 
cells have shown improvements in heart functional recovery and skeletal muscle and liver 
regeneration.
18,65,69
 
The enhanced regenerative potential of MSCs within a hypoxic environment can 
potentially be attributed to the fact that MSCs show increased expression and secretion of 
pro-angiogenic and pro-survival factors, including HIF, angiopoietin 1, VEGF, Flk-1, 
erythropoietin, FGF, and MMP-2.
18,19,65,70,71
 Stem cells have also been shown to secrete 
immunomodulatory factors, including indoleamine 2,3-dioxygenase (IDO),
72
 interferon-
gamma (IFN-γ),72 tumor necrosis factor-alpha (TNF-α),72,73 macrophage inflammatory 
protein (MIP),
17
 and interleukins
71,73
 when exposed to hypoxia. As a result, the paracrine 
action of MSCs can modulate surrounding host cells, such as endothelial cells and 
macrophages.
17,74
 In fact, recent literature has suggested that macrophages may be altered 
through the interaction with MSCs, leading to accelerated and more improved tissue 
regeneration.
75-77
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1.1.5 The role of macrophages in wound healing 
Effective wound healing and tissue repair requires the orchestrated actions of 
many cell types. Following an injury, macrophages quickly infiltrate the area and are 
instrumental in initiating the immune response. Macrophages have been shown to have 
key roles in wound healing, angiogenesis, and skeletal muscle repair. Thus, 
understanding the contribution of macrophages to these processes, as well as the 
influence of the environment on macrophage function, is essential for monitoring wound 
healing and optimizing therapies. 
Dynamic changes in macrophage populations are essential for efficient wound 
healing.
78
 Specifically in skeletal muscle injuries, recruitment of pro-inflammatory 
monocytes within the first few days following injury is required in order to clear debris 
and release cytokines that stimulate myoblast proliferation.
75,77,79,80
 Furthermore, 
impairment of monocyte/macrophage recruitment during the early stages prevents muscle 
repair.
75,77,79
 However, conversion into an anti-inflammatory macrophage population is 
necessary for complete wound repair, as anti-inflammatory macrophages promote 
myoblast differentiation and fusion in skeletal muscle.
75-77,80
 In ischemic tissues 
following myocardial infarction, the phenotypic changes of macrophages in response to 
the interactions with stem cells can be a critical factor, with the external environment 
dictating the transition from pro- (M1) to anti-inflammatory (M2) macrophages.
76,77,79,80
 
M2 macrophages are known to have a more “regenerative” role compared to M1 pro-
inflammatory macrophages.
81
 Differentiation stimuli include cytokine secretion by 
surrounding cells and by macrophages themselves, as well as phagocytosis of debris and 
apoptotic cells by macrophages. In particular, interferon-γ (IFN-γ) and TNF-α polarize 
macrophages to an M1 phenotype, while interleukin (IL)-4, IL-10, and IL-13 polarize 
macrophages to an M2 phenotype.
76,80
 Thus altering these factors may influence 
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macrophage phenotype and wound healing. Figure 1.2 outlines the different macrophage 
phenotypes, including stimulating factors, secreted cytokines and chemokines, and 
expressed surface markers. 
It has been demonstrated that MSC therapy significantly affects macrophage 
subpopulations and, subsequently, wound repair.
82
 The mechanisms responsible for this 
could potentially be attributed to the pro-angiogenic role of macrophages, including 
physically interacting with sprouting blood vessels, facilitating the growth of blood 
vessels by degrading the extracellular matrix, and promoting vascular remodeling via 
VEGF-independent angiogenic pathways.
83
 In addition, macrophages have been 
suggested to have different pro-angiogenic mechanisms depending on their phenotype 
(M1 vs M2).
83,84
  
1.2 OVERALL RESEARCH GOALS 
The overall goal of this research is to evaluate the use of bone marrow-derived 
mesenchymal stem cells delivered within a PEGylated fibrin gel biomatrix for 
revascularization therapies. The hypothesis is that (1) MSCs delivered via an injectable 
PEGylated fibrin matrix will contribute to increased vascularization and regeneration of 
ischemic tissue and (2) this repair mechanism can be attributed to paracrine effects of 
MSCs and the interaction with macrophages. 
The research presented here addresses the overall hypothesis by (1) determining 
the feasibility of nanoparticle labeling of MSCs in vitro, (2) optimizing the nanoparticle 
system for in vivo monitoring of MSCs and infiltrating macrophages, (3) assessing the 
influence of a hypoxic environment on MSC function and the interaction with 
macrophages, and (4) demonstrating the extent of neovascularization and muscle function 
improvement in vivo following delivery of MSCs within a PEGylated fibrin biomatrix.  
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Chapter 2 outlines the initial studies in investigating nanoparticle labeling of 
MSCs with various spherical nanoparticle formulations. Nanoparticle uptake and the 
resulting effects on cell viability and function were assessed for different nanoparticle 
sizes and surface coatings. Chapter 3 investigates the design of a dissociative 
nanoparticle system in order to evade macrophage uptake and accumulation in organs and 
tissues in vivo. Chapter 4 expands upon the work in Chapter 3 by developing a dual 
nanoparticle system to label both MSCs and macrophages. Characterization of the 
nanoparticles was performed, as well as assessing the specificity of nanoparticle labeling 
of the cell types in vitro and in vivo. Chapter 5 attempts to understand the role of hypoxia 
on stem cell function and the resulting implications for wound healing in terms of 
immunomodulation. Chapter 6 presents the investigation of MSC therapy within an in 
vivo hind limb ischemia model. The contribution of MSCs delivered within a PEGylated 
fibrin gel to functional recovery of the tissue and vascular regeneration were evaluated. 
Chapter 7 outlines overall conclusions, recommendations for future work, and the broad 
implications of this research. 
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Study 
Cell Type 
(delivery route) 
Clinical Outcome 
Bartsch85 
Bone marrow 
mononuclear cells (IM 
and IA) 
2 months: improvements in ABI, capillary-venous 
oxygen saturation, mean reactive hyperemia, and 
pain free walking distance 
Cobellis86 
Bone marrow 
mononuclear cells (IA) 
12 months: substantial improvement of blood flow 
and increased capillary densities; ABI and pain free 
walking distance improved significantly 
Walter87 
Bone marrow 
mononuclear cells (IA) 
3 months: no significant improvements in ABI; 
significantly improved ulcer healing and reduced 
rest pain; limb salvage and amputation free survival 
rates did not differ between groups 
Idei88 
Bone marrow 
mononuclear cells (IM) 
4 years: improvements in amputation free rates and 
survival rates; ABI and tcpO2 significantly 
increased after 1 month and gradually decreased 
during 3 year follow up and returned to baseline 
Benoit89 
Bone marrow-derived 
stem cells (IM) 
6 months: lower amputation rate; no differences in 
ABI 
Powell90 
Bone marrow tissue 
repair cells (IM) 
12 months: decreased amputation rate, and 
improved wound healing 
Losordo91 CD34+ cells (IM) 6 and 12 months: decreased amputation rate 
Amann92 Bone marrow cells (IM) 
3 and 6 months: increased ABI, tcpO2, and total 
walking distance 
Iafrati93 
Bone marrow aspirate 
concentrate (IM) 
1, 4, 8, and 12 weeks: Decreased amputation rate 
and improved pain, ABI, Rutherford classification, 
and quality of life scoring 
Highashi94 
Bone marrow 
mononuclear cells (IM) 
4 and 24 weeks: improved ABI, tcpO2, and pain-
free walking time 
Ishida95 
Peripheral blood 
mononuclear cells (IM) 
4 weeks: improvement in ABI, ischemic ulcers, 
mean walking distance, and physiological 
functioning 
Chochola96 
Bone marrow 
mononuclear cells (IM) 
1 year: decreased amputation rate and 
improvements in grade of ischemia and wound 
healing 
Durdu97 
Bone marrow 
mononuclear cells (IM) 
6 months: improvements in ABI, rest pain scores, 
quality of life, wound healing, and collateral 
network formation across affected arteries 
Saito98 
Bone marrow 
mononuclear cells (IM) 
4 and 24 weeks: rest pain significantly reduced and 
ulcers healed and diminished in size 
 
Table 1.1:  Summary of clinical trials investigating therapeutic delivery of mesenchymal 
stem cells to ischemic skeletal muscle. Abbreviations: intraarterial (IA), 
intramuscular (IM), ankle-brachial index (ABI), transcutaneous oxygen 
pressure (tcpO2). 
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Figure 1.1: Optical absorption and extinction coefficients of various endogenous tissues. 
Abbreviations: deoxygenated hemoglobin (Hb), oxygenated hemoglobin 
(HbO2). 
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Figure 1.2:  (A) The spectrum of macrophage phenotypes, including stimulating factors, 
secreted cytokines and chemokines, and expressed surface markers. (B) Time 
course of macrophage infiltration and phenotype expression following an 
ischemic injury.  
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Chapter 2: In vitro evaluation of nanoparticle labeling of mesenchymal 
stem cells 
2.1 INTRODUCTION 
Stem cells are advantageous in that they can potentially be used for cellular 
therapies due to the fact that they can differentiate into multiple cell types,
1
 including 
cardiovascular cell types.
2-5
 Previous work by our group demonstrated that PEGylated 
fibrin gels promote mesenchymal stem cell (MSC) tubulogenesis and differentiation 
towards a vascular cell type.
4
 These findings suggest MSCs could potentially be 
delivered to an injury site after an ischemic event in order to assist in neovascularization 
and tissue repair.
3-7
 However, the exact mechanisms of vascular repair, as well as the role 
and extent of participation of MSCs in neovascularization, are not well understood.  
To this end, there have been numerous proposed approaches for long-term 
tracking of stem cells in vivo. A majority of this research has focused on labeling MSCs 
in vitro, delivering the MSCs in vivo, and sacrificing the animals at various time points 
and performing histology.
8
 However, a major issue with this methodology is the inability 
to track the cells within a single, live animal model over time. As a result, many 
investigators have turned to noninvasive imaging modalities which are capable of 
longitudinally monitoring and tracking stem cells within a single model.
9-11 
The imaging approaches previously investigated require the use of contrast agents 
to label the cells. Efficient cell labeling with contrast agents is necessary in order to 
adequately image and track MSCs. For long-term imaging, it is desirable to have contrast 
agents which have long-term stability, are not toxic to the cells, and do not affect cell 
function. Radionuclides have short half-lives,
12
 and thus are not ideal for long-term 
imaging studies. Reporter genes indirectly label cells and are not diluted as a result of cell 
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division.
13
 However, the cells need to be genetically manipulated, which could alter cell 
function, and a substrate must be administered intravenously for each imaging session.
13
 
Nanoparticles provide an advantage over radionuclides, in that they can be used for long-
term imaging and allow for repeated imaging over time.
12,14-17
 Although nanoparticle 
labeling can decrease over time due to cell division, certain nanoparticle materials, such 
as gold, are not toxic to the cells and do not alter cell function.
16
  
Taking into account the advantages and disadvantages of the various contrast 
agents which can be employed, gold nanoparticles were investigated as a contrast agent 
for stem cell tracking. Gold nanoparticles offer many advantages, including their 
optically tunable properties and inert characteristics. In addition, photoacoustic imaging 
can be used to image cells labeled with gold nanoparticles.
18,19
 Photoacoustic imaging 
can be used for in vivo imaging at reasonable depths,
20
 as well as for longitudinal 
studies.
21,22
 Specifically, the long term goal of this study is to optically assess how MSCs 
delivered in vivo via a PEGylated fibrin gel participate in the process of 
neovascularization. In this study, the efficiency of MSC labeling with gold nanoparticles 
and the effects of nanoparticle loading on cell function were assessed. Initial nanoparticle 
loading and retention over time were determined in order to evaluate the feasibility of 
long-term imaging of MSCs. This study provides a first step in achieving the goal of 
tracking the migration of MSCs delivered in vivo using PEGylated fibrin gels in order to 
assess the role of MSCs in the process of neovascularization and tissue repair. A better 
understanding of the process of neovascularization, and the extent to which MSCs 
participate in this process, can potentially lead to the development of better therapies for 
tissue repair.  
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2.2 MATERIALS AND METHODS 
2.2.1 Human MSC culture 
Human mesenchymal stem cells (hMSCs) (Lonza, Walkersville, MD) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% penicillin-
streptomycin. The cell culture media was changed every 2-3 days. Cells were passaged 
using 0.25% trypsin/EDTA (Lonza), collected by centrifugation at 600 x g for 7 minutes, 
and counted with trypan blue exclusion. For all experiments, cells were seeded at a 
density of 5,000 cells/cm
2
. Cells were grown under standard cell culture conditions 
(37°C, 5% CO2). Passage 5-8 hMSCs were used in this study. 
2.2.2 Nanoparticle synthesis 
Gold nanoparticles were synthesized via citrate reduction of tetrachloroauric (III) 
acid (HAuCl4) under reflux. Gold nanoparticles of various sizes (20 nm, 40 nm, and 60 
nm) were synthesized by varying the percentage of sodium citrate. Gold nanoparticles 
were coated with poly-L-lysine (1-5 kD) by adding 120 µL of poly-L-lysine/mL of 
nanoparticle solution and allowed to mix for 30 minutes. Poly-L-lysine hydrobromide 
(Sigma-Aldrich, St. Louis, MO) was dissolved in distilled water prior to use.  
2.2.3 Nanoparticle characterization 
A DelsaNano (Beckman Coulter, Inc., Brea, CA) was used to determine the size and 
zeta potential of citrate-stabilized (CS) and poly-L-lysine (PLL) coated gold 
nanoparticles in water and in cell culture media. Briefly, nanoparticle solutions were 
loaded into a glass cuvette and readings were taken at a temperature of 25°C. For size 
measurements, 5 repetitions were performed for each nanoparticle solution with 60 
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readings per repetition. For zeta potential measurements, 3 repetitions were performed for 
each nanoparticle solution with 5 readings per repetition.  
An FEI Tecnai transmission electron microscope operating at 80 kV and fitted with a 
top mount AMT Advantage HR 1kX1k digital camera was used to determine the size and 
shape of citrate-stabilized and poly-L-lysine coated gold nanoparticles in water and in 
cell culture media. Images were taken at 135kx magnification. Prior to imaging, carbon 
coated copper 300 mesh grids (Electron Microscopy Sciences, Hatfield, PA) were placed 
in the nanoparticle solutions and allowed to incubate for approximately 2 minutes. The 
grids were then removed from the solution and allowed to dry. 
2.2.4 Nanoparticle incubation and assessment of cell uptake 
Cells were cultured as described in section 2.2.1. Nanoparticle media was made 
by centrifuging the nanoparticle solutions (5000 x g for 15 minutes for 20 nm citrate-
stabilized nanoparticles and 3220 x g for 30 minutes for all other nanoparticle solutions) 
and resuspending the pellet in phenol red free media at a concentration of approximately 
10
12
 nanoparticles/mL. MSC growth media was aspirated from the flasks and 200 µL/cm
2
 
of nanoparticle media was added to the cell culture and allowed to incubate for 24 hours. 
After 24 hours, the nanoparticle media was removed and the cells were washed with 
phosphate-buffered saline (PBS). A Leica DMI2000B microscope equipped with a Leica 
DFC290 camera was used to obtain dark field images in order to assess nanoparticle 
uptake. 
2.2.5 LIVE/DEAD staining 
In order to assess cell viability after nanoparticle uptake, a LIVE/DEAD stain was 
performed. Briefly, stock solutions of calcein AM (4 mM) and ethidium homodimer-1 (2 
mM) were diluted in PBS to a final working concentration of 4 µM and 1 µM, 
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respectively. MSC growth media was removed from the wells and the cells were washed 
two times in PBS. The cells were then incubated in the LIVE/DEAD stain for 45 minutes 
at 37°C, after which they were washed two times in PBS. The stained cells were then 
imaged using fluorescence microscopy (Leica DMI2000B microscope equipped with a 
Leica DFC290 camera). Control cells consisted of cells not incubated with nanoparticles. 
Cell viability was assessed at various time points over a two week period. 
2.2.6 MTT assay 
A Sigma-Aldrich MTT Cell Proliferation Assay kit was used to perform the MTT 
assay. Briefly, MTT reagent was added to cells at a ratio of 100 µL/mL of media. The 
samples were incubated for 3 hours at 37°C. The detergent reagent was then used to lyse 
the cells. A universal microplate reader ELX800 (Bio-Tek Instruments Inc., Winooski, 
VT) was used to measure the absorbance values of the samples at 562 nm and a reference 
wavelength of 630 nm. Control cells consisted of cells not incubated with nanoparticles. 
A blank sample containing no cells was used and subtracted from all measurements. 
Cytotoxicity was assessed over a one week period at various time points. Triplicate 
samples were used and the assay was performed twice. 
The number of cells was calculated using a standard curve. A one-way ANOVA, 
followed by t-tests for multiple comparisons, was used to statistically compare the 
experimental conditions to the control condition at the same time point (p<0.01). 
2.2.7 MSC differentiation 
The ability of the cells to exhibit bipotent differentiation (i.e. adipogenic and 
osteogenic) after nanoparticle uptake was assessed for all nanoparticle conditions. 
Control cells consisted of cells not incubated with nanoparticles and which were induced 
to differentiate into the specified lineages. Negative control cells consisted of cells not 
 30 
incubated with nanoparticles and which were not induced to differentiate into the 
specified lineages.  
Briefly, adipogenesis was induced by plating cells at a density of 2.1 x 10
4
 
cells/cm
2
 and allowing the cells to grow to confluency. After the cultures reached 100% 
confluence, the growth media was replaced with adipogenic induction media (DMEM, 
10% FBS, 1% penicillin-streptomyocin, 1% glutamax, 1 µM dexamethasone (Sigma-
Aldrich, St. Louis, MO), 10 µg/mL 3-isobutyl-1-methylxanthine (Sigma-Aldrich, St. 
Louis, MO), 10 µg/mL insulin (Sigma-Aldrich, St. Louis, MO), and 100 µM 
indomethacin (Sigma-Aldrich, St. Louis, MO)). After three days, the adipogenic 
induction media was replaced with adipogenic maintenance media for one day (DMEM, 
10% FBS, 1% penicillin-streptomyocin, 1% glutamax, 10 µg/mL insulin). Three cycles 
of induction/maintenance were performed, after which the cells were incubated in 
adipogenic maintenance media for seven days. Control cells were supplemented only 
with adipogenic maintenance media. Oil red O (Sigma-Aldrich, St. Louis, MO) staining 
was used to assess adipogenesis. The cells were fixed in 10% formalin and then 
incubated in 60% isopropanol for 4 minutes. The cells were then incubated in oil red O 
staining solution for 5 minutes, rinsed in tap water, and counterstained in hematoxylin for 
1 minute. After washing with tap water, the slides were mounted and viewed under phase 
contrast using a Leica DMI2000B microscope equipped with a Leica DFC290 camera. 
Osteogenesis was induced by plating cells at a density of 3.1 x 10
3
 cells/cm
2
. The 
cells were allowed to adhere for 24 hours, after which the media was replaced with 
osteogenic induction media (DMEM, 10% FBS, 1% pencillin-streptomyocin, 1% 
glutamax, 50 µg/mL ascorbic acid, 100 nM dexamethsone (Sigma-Aldrich, St. Louis, 
MO), and 10 mM beta-glycerophosphate disodium salt hydrate (Sigma-Aldrich, St. 
Louis, MO)). Osteogenesis was induced over a period of two weeks, after which a von 
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Kossa staining kit (Fisher Scientific) was used to assess osteogenesis. The cells were 
fixed in 10% formalin and then incubated in 5% silver nitrate for 40 minutes with 
exposure to an ultraviolet light. The cells were washed in distilled water and then placed 
in 5% sodium thiosulfate for 2 minutes, after which they were rinsed in tap water and 
placed in nuclear fast red stain for 5 minutes. After washing with tap water, the slides 
were mounted and viewed under bright field using a Leica DMI2000B microscope 
equipped with a Leica DFC290 camera. 
2.2.8 Inductively coupled plasma mass spectrometry 
Initial nanoparticle loading and retention over a two week period were assessed 
for cells incubated with 20 nm citrate-stabilized nanoparticles using inductively coupled 
plasma mass spectrometry (ICP-MS). Cells were cultured and incubated with 
nanoparticles for 24 hours as described in section 2.2.3. After 24 hours, the nanoparticle 
media was removed and the cells were washed two times with PBS. The cells were then 
incubated in growth media without nanoparticles and collected at the designated time 
points. Cell media was changed every 2-3 days and the cells were passaged after reaching 
~80% confluence. 
At the designated time points the cells were collected, centrifuged, and 
resuspended in 300 µL of 70% nitric acid and incubated at 60°C for 14 hours, after which 
the cells were diluted 100x in nanopure water. A standard curve was used to quantify the 
amount of gold in the cells. Briefly, standard solutions were made by diluting AAS gold 
standard (Sigma-Aldrich, St. Louis, MO) in the same background solution as that of the 
cell solutions. All measurements were made using triplicate samples. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Nanoparticle characterization 
Nanoparticle size was analyzed using transmission electron microscopy (TEM) 
and dynamic light scattering (DLS). In addition, nanoparticle shape and zeta potential 
were assessed using TEM and DLS, respectively. Using DLS, the average size of the 
three nanoparticle formulations (i.e. citrate-stabilized nanoparticles in water) were 
determined to be 23.1 ± 4.14 nm, 49.78 ± 9.18 nm, and 57.58 ± 10.72 nm (Table 2.1), 
and were designated as 20 nm, 40 nm, and 60 nm, respectively. In addition, 
representative TEM images of 20 nm, 40 nm, and 60 nm citrate-stabilized (CS) 
nanoparticles in water are shown in Figures 2.1A, B, and C, respectively. 
 Coating the gold nanoparticles with poly-L-lysine (PLL) caused the zeta potential 
of the nanoparticles in water to go from negatively charged (approximately -30 mV) to 
positively charged (approximately +30 mV), as determined using a DelsaNano. There 
was also a slight increase in the average size of the nanoparticles after coating with PLL 
(Table 2.1). It should be noted that 20 nm particles most likely undergo aggregation in 
the presence of PLL.  
2.3.2 MSC nanoparticle loading 
MSC nanoparticle loading was assessed using dark field microscopy. Control 
cells were not incubated with nanoparticles and appear as a faint blue (Figure 2.2A). Due 
to the faint appearance of the control cells under dark field, a phase contrast image of the 
control cells is provided in Figure 2.2A1 to verify the presence of cells. 
Nanoparticle loaded cells appear a yellow-orange color when observed under dark 
field microscopy, as compared to cells not loaded with nanoparticles, which appear blue. 
The dark field images show that cells were loaded with 20 nm, 40 nm, and 60 nm CS 
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nanoparticles after 24 hour incubation (Figures 2.2B, D, and F, respectively), as 
evidenced by the yellow-orange appearance of the cells. In addition, cells were loaded 
with 20 nm, 40 nm, and 60 nm PLL coated nanoparticles after 24 hour incubation 
(Figures 2.2C, E, and G, respectively), as evidenced by the yellow-orange appearance of 
the cells.  
Cells were also incubated with 20 nm, 40 nm, and 60 nm gold nanoparticles 
coated with polyethylene glycol (PEG), but did not exhibit nanoparticle uptake. Instead, 
cells incubated with PEGylated nanoparticles more closely resembled the control cells. 
However, MSC nanoparticle loading was not expected for cells incubated with 
PEGylated nanoparticles because of the well-documented evidence of PEG as a 
stealthing agent.
23,24
 Due to the fact that the nanoparticle formulations used in this study 
did not incorporate targeting agents (e.g. targeting antibodies), nanoparticle uptake by 
cells was passive, and thus MSCs were unable to detect and passively uptake PEGylated 
nanoparticles. 
2.3.3 MSC viability and cytotoxicity 
 MSC viability and cytotoxicity after nanoparticle loading was assessed using a 
LIVE/DEAD stain and an MTT assay. The effect of nanoparticle loading on MSC 
viability was assessed over a two week period at various time points. The time points 
(day 1, day 7, and day 14) correspond to the number of days after initial nanoparticle 
incubation. The results of the LIVE/DEAD assay are shown in Figure 2.3A. Green cells 
were considered live and red cells were considered dead. Control cells were not incubated 
with nanoparticles. As evident from the representative LIVE/DEAD images in Figure 
2.3A, the cells remained viable for all nanoparticle formulations over a two week period, 
and there was minimal cell death present (indicated by white arrows). 
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 Nanoparticle cytotoxicity was assessed at various time points over a one week 
period using an MTT proliferation assay. The time points (day 1, day 4, and day 7) 
correspond to the number of days after initial nanoparticle incubation. The cell numbers 
were quantified using a spectrophotometer and a standard curve. Control cells were not 
incubated with nanoparticles. The results for the MTT assay are shown in Figure 2.3B. It 
should be noted that the nanoparticles loaded within the cells did not contribute to the 
absorbance readings. Cell numbers for the various nanoparticle formulations were 
statistically compared to the control condition for the corresponding day. It was found for 
day 1 that cells loaded with 20 nm CS and 60 nm CS nanoparticles had a significantly 
lower cell number compared to control cells (p<0.01). In addition, on day 7, cells loaded 
with 60 nm PLL nanoparticles had a significantly lower cell number compared to control 
cells (p<0.01). 
2.3.4 MSC differentiation 
 The bipotent ability of MSCs to differentiate to adipogenic and osteogenic 
lineages after nanoparticle loading was assessed in order to determine if MSC function 
was maintained after nanoparticle loading. Control (+) cells were not incubated with 
nanoparticles and were induced to differentiate and Control (-) cells were not incubated 
with nanoparticles and were not induced to differentiate.  
Figure 2.4A shows the results of oil red O staining for assessing adipogenesis. 
Fatty, lipid deposits were stained red (indicated by white arrows) and are indicative of 
adipogenesis. The ability of MSCs to differentiate into adipocytes was maintained for all 
nanoparticle formulations, as qualitatively assessed by comparing the control images to 
the nanoparticle loaded MSC images. As expected, Control (-) cells did not exhibit any 
lipid deposits, as indicated by the negative staining. 
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Figure 2.4B shows the results of von Kossa staining for assessing osteogenesis. 
Calcium deposits were stained black (indicated by red arrows) and are indicative of 
osteogenesis. The ability of MSCs to differentiate into osteocytes was maintained for all 
nanoparticle formulations, as qualitatively assessed by comparing the control images to 
the nanoparticle loaded MSC images. Control (-) cells did not exhibit any calcium 
deposits.  
2.3.5 MSC nanoparticle uptake and retention 
 Initial nanoparticle loading and retention over a two week period were determined 
for MSCs loaded with 20 nm CS gold nanoparticles using ICP-MS (Figure 2.5A). The 
average number of nanoparticles/cell decreased by approximately an order of magnitude 
over a two week period from 4.53 x 10
5
 ± 3.98 x 10
3
 nanoparticles/cell to 2.00 x 10
4
 ± 
2.18 x 10
2 
nanoparticles/cell. Also, the number of nanoparticles/cell decreased 
exponentially over a two week period. Figure 2.5B compares the average number of 
nanoparticles/cell and cell proliferation rate for cells loaded with 20 nm CS nanoparticles. 
The data was normalized to the maximum value for the corresponding data set. Day 7 
was the only data point that had a significant difference between the ICP-MS and cell 
proliferation data (p<0.01), as determined using a Student’s t-test. 
2.4 CONCLUSIONS 
 Previous work has demonstrated that PEGylated fibrin gels promote MSC 
differentiation and tubulogenesis.
4
 Many investigators have suggested delivering stem 
cells to an injury site (e.g. myocardial infarction) in order to promote wound healing and 
retain normal physiological function.
2-4,25,26
 However, it is not clear if the MSCs 
implanted within the gels are actively participating in neovascularization in vivo, and, if 
so, what the specific role of the delivered MSCs is in neovascularization. Thus, this study 
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evaluated labeling MSCs with gold nanoparticles in order to track and monitor MSCs 
over time in vivo after delivery. The specific aims of this study were to determine if 
nanoparticle loading of MSCs with gold nanoparticles was possible, and also to assess if 
MSC function was compromised as a result of nanoparticle loading. To this end, the 
results of this study demonstrate the feasibility of loading MSCs with gold nanoparticles 
in order to track the MSCs in vivo. Specifically, MSCs were loaded with 20 nm, 40 nm, 
and 60 nm CS and PLL coated gold nanoparticles. In addition, nanoparticle loading did 
not substantially affect MSC viability or proliferation and MSCs were still able to 
differentiate into adipogenic and osteogenic lineages. 
MSC nanoparticle loading was accomplished via passive uptake of the 
nanoparticles by the cells because no targeting agents were used to promote nanoparticle 
uptake. The nanoparticles aggregated when resuspended in cell culture media, as evident 
from the change in color of the nanoparticle solution from deep red to light blue, as well 
as the presence of peak broadening in the absorbance spectrum. Nanoparticle aggregation 
can most likely be attributed to the adsorption of serum proteins onto the nanoparticle 
surface. It is possible that protein adsorption could promote nanoparticle uptake by the 
cell. 
 It is interesting to note that the PLL nanoparticles did not have a negative effect 
on MSC function. Other investigators have found that high concentrations of PLL induce 
cell toxicity.
27
 However, PLL is commonly used to coat substrates in low concentrations 
in order to promote cell adhesion, with no negative effects on cell viability. In this study, 
the cells were exposed to a low concentration of PLL coating the nanoparticles, and, as a 
result, cell toxicity was not induced. In fact, previous investigators have also found that 
PLL in low concentrations, such as that used for coating nanoparticles, is not toxic to 
cells.
28,29 
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 The results of this study also demonstrate that nanoparticle loading decreased 
exponentially over time. The decrease in nanoparticle loading over time could be 
attributed to both cell division and exocytosis of the nanoparticles by the cells. The 
normalized data for the average number of nanoparticles/cell and the inverse of the cell 
number over time exhibit a similar trend, with what appears to be an exponential decrease 
over time. Of the three time points analyzed, only day 7 had a statistically significant 
difference between the ICP-MS and cell proliferation data. Thus, it was concluded that at 
the later time points, cell division was not the only factor responsible for the decrease in 
nanoparticle retention over time, and additional mechanisms, such as nanoparticle 
exocytosis, also significantly contributed to the observed results. However, as evidenced 
by the results, a majority of the decrease in nanoparticle retention over time was due to 
cell division.  
Regardless of the mechanisms responsible for the decrease in the number of 
nanoparticles/cell, the decrease in nanoparticle retention over time has implications on 
the ability to image cells over long time periods. That is, a significant decrease in 
nanoparticle loading over time corresponds to a substantial decrease in signal when 
imaging. However, previous investigators have demonstrated the ability to use 
photoacoustic imaging, which is a noninvasive imaging approach that is capable of 
imaging cells at sufficient depths in vivo, to image human epithelial carcinoma cells.
18
 
The cells were also imaged in vitro and loaded with 50 nm EGFR-targeted gold 
nanospheres at a concentration almost an order of magnitude lower than that exhibited by 
MSCs after two weeks.
18
 Thus, longitudinally imaging MSCs loaded with gold 
nanoparticles using photoacoustic imaging should be feasible. 
 The end goal of this study is to develop an imaging technique which can visualize 
and track MSCs at sufficient depths and spatial/temporal resolutions. Specifically, using a 
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noninvasive imaging approach which is capable of optically tracking MSCs in vivo over 
long time periods within a single animal model is ideal. Optical imaging modalities 
which could be employed to monitor and track MSCs include photoacoustic imaging,
18,19
 
confocal microscopy,
30
 two-photon microscopy,
31
 and optical coherence tomography.
32,33 
In summary, the presented work demonstrates the ability to load MSCs with gold 
nanoparticles of various sizes and surface coatings. In addition, this study also 
demonstrates that MSC function is not altered by nanoparticle loading. Furthermore, 
these findings lend to the possibility of longitudinal imaging MSCs in vivo in order to 
better understand the participation and role of MSCs in neovascularization. 
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Table 2.1: Dynamic light scattering was used to determine the average size of the 
nanoparticle formulations. Results are shown as average nanoparticle size ± 
standard deviation. Reprinted with permission from Ricles et al.
34
 Copyright 
2011 Dove Medical Press. 
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Figure 2.1:  Representative TEM images of (A) 20 nm, (B) 40 nm, and (C) 60 nm 
citrate-stabilized gold nanoparticles in water. Scale bars = 100 nm. 
Reprinted with permission from Ricles et al.
34
  Copyright 2011 Dove 
Medical Press. 
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Figure 2.2: Dark field images of MSCs incubated for 24 hours with (B) 20 nm citrate-
stabilized, (C) 20 nm poly-L-lysine, (D) 40 nm citrate-stabilized, (E) 40 nm 
poly-L-lysine, (G) 60 nm citrate-stabilized, and (G) 60 nm poly-L-lysine 
media. (A) A control dark field image and (A1) phase contrast image of 
MSCs not incubated with nanoparticles is shown for comparison. Scale bars 
= 100 µm. Abbreviations: citrate-stabilized (CS), poly-L-lysine (PLL). 
Reprinted with permission from Ricles et al.
34
 Copyright 2011 Dove 
Medical Press. 
  
 42 
 
Figure 2.3: (A) Representative LIVE/DEAD images of cells incubated with 
nanoparticles for 24 hours and assessed at various time points after 
nanoparticle removal over a two week period. Cells which appear green 
were considered live and those which appear red were considered dead 
(indicated by white arrows). Scale bar = 100 µm. (A) An MTT assay was 
used to assess nanoparticle cytotoxicity by quantifying cell number over a 
one week period. Data is shown as an average ± standard deviation. 
Significantly lower differences in cell number from the control for the 
corresponding day are indicated by an asterisk (* = p<0.01). Abbreviations: 
citrate-stabilized (CS), poly-L-lysine (PLL). Reprinted with permission from 
Ricles et al.
34
  Copyright 2011 Dove Medical Press. 
  
 43 
 
Figure 2.4: The bipotent ability of MSCs to differentiate to adipogenic and osteogenic 
lineages was assessed after 24 hour nanoparticle incubation. Control cells 
were not incubated with nanoparticles. Control (+) cells were induced to 
differentiate and Control (-) cells were not induced to differentiate. (A) Oil 
red O staining was used to assess adipogenic differentiation by staining for 
lipid deposits (white arrows). (B) Von Kossa staining was used to assess 
osteogenic differentiation by staining for calcium deposits (red arrows). 
Scale bar = 100 µm. Reprinted with permission from Ricles et al.
34
  
Copyright 2011 Dove Medical Press. 
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Figure 2.5: (A) Nanoparticle uptake and retention over a two week period were assessed 
using ICP-MS for cells incubated with 20 nm citrate-stabilized nanoparticles 
for 24 hours. The results are shown as the average number of 
nanoparticles/cell ± standard error. (B) Comparison of the normalized 
values for the average number of nanoparticles/cell and the inverse of cell 
proliferation over time for cells labeled with 20 nm citrate-stabilized 
nanoparticles. The results are shown as the average values ± standard 
deviation. Reprinted with permission from Ricles et al.
34
  Copyright 2011 
Dove Medical Press. 
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Chapter 3: Investigation of a dissociative nanoparticle system for 
efficient clearance 
3.1 INTRODUCTION 
The ideal contrast agent for stem cell monitoring should not only be safe and 
nontoxic, but also have minimal transfer to non-stem cells and be efficiently cleared from 
the body. If the contrast agent is not efficiently cleared, it could lead to accumulation in 
organs and tissues, resulting in toxicity. In addition, transfer of contrast agents to non-
stem cells would result in tracking the incorrect cell type, which is especially a concern 
when monitoring cell-based therapies.  
Following intravenous delivery, nanoparticle blood residence time and the route 
of clearance is dependent upon the size and surface coating of the nanoparticle.
1-3
 
Nanoparticle retention in the blood increases with nanoparticle size, while the extent of 
renal clearance decreases with increasing size, as shown in Figure 3.1. The cross-over 
point between the two curves exists at a hydrodynamic diameter of 5-6 nm, meaning that 
nanoparticles within that size range are rapidly cleared from the body via renal 
filtration.
1-3
 On the other hand, larger nanoparticles are found to be sequestered and 
cleared by Kupffer cells in the liver and macrophages in the spleen.
2-4
 Kupffer cells and 
macrophages are part of the reticuloendothelial system (RES), consisting of phagocytic 
cells which clear debris and foreign substances from the body.
5
 Renal filtration is 
desirable because of the intracellular catabolism associated with hepatic clearance.
2
 
In addition to affecting clearance, nanoparticle size also affects cellular uptake. 
Chithrani et al found that the optimal size for nanoparticle uptake was a hydrodynamic 
diameter of 50 nm.
6
 Smaller nanoparticles require clustering of the particles together on 
the surface of the membrane in order for endocytosis to take place. This can be attributed 
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to the free energy requirements for membrane wrapping of the nanoparticle.
6
 On the other 
hand, particles larger than 50 nm require more membrane receptor interactions.
6,7
 
However, the slow diffusion kinetics of the receptors results in slow membrane wrapping 
time, leading to a smaller number of nanoparticles being taken up by the cell.
6
 
Another ideal requirement for contrast agents for stem cell tracking is minimal 
transfer to non-stem cells. Other investigators have found nanoparticle transfer to 
macrophages in vivo,
8-10
 resulting in the monitoring and tracking of macrophages instead 
of the delivered stem cell therapy. One study monitored quantum dot labeled stem cells 
delivered into a bone defect model.
11
 However, after 7 days, fluorescent signals were 
observed at the contralateral sites. Histological analysis revealed that this signal was not 
from stem cells, but instead from macrophages, as a majority of the quantum dots in both 
limbs were associated with macrophages.
11
 As a result, the investigators were monitoring 
what appeared to be stem cells, but were in fact macrophages. In another study, stem cells 
were labeled with superparamagnetic iron oxide particles and transduced with a 
fluorescent protein.
10
 Longitudinal magnetic resonance (MR) imaging showed signals up 
to 4 weeks, whereas bioluminescence imaging showed a progressive decrease in signal 
over time.
10
 Histological analysis revealed that most of the iron oxide nanoparticles were 
taken up by macrophages, accounting for the persistent MR signals.
10
 It appeared that a 
majority of the stem cells had died, causing the decrease in bioluminescence signal. 
However, MR imaging is unable to distinguish viable from non-viable cells. As a result, 
the apoptotic stem cells were most likely endocytosed by macrophages, resulting in the 
MR signal to be generated from the macrophages.
10
 Overall, these studies demonstrate 
that monitoring of stem cells using nanoparticle labeling has a drawback of not being able 
to distinguish the transfer of contrast agents to non-stem cells.  
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This study attempts to address the issue of nanoparticle transfer using a 5 nm 
nanoparticle contrast agent. Since cells do not readily detect and take up 5 nm gold 
nanoparticles, the nanoparticles were aggregated using a poly-L-lysine coating. The 
hypothesis is that the particles will dissociate within endosomal compartments with 
minimal biologic effects and will not accumulate in subsequent cell populations or in 
organs in vivo. Non-stem cells, such as macrophages, are less likely to take up 
nanoparticles exocytosed from MSCs which are 5 nm in diameter compared to larger 
nanoparticles. This is due to the fact that cells do not readily take up smaller 
nanoparticles (i.e. smaller than 50 nm) and the nanoparticles will be cleared more rapidly 
from the system, providing less time for macrophages to take up the nanoparticles. 
3.2 MATERIALS AND METHODS 
3.2.1 Cell culture 
Rat mesenchymal stem cells were isolated from the bone marrow of Lewis rats 
(200-300 g). The femoral marrow cavity was flushed and adherent cells were collected 
and cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% penicillin-
streptomyocin. Non-adherent cells were removed after 24 hours by replacing the media. 
The media was then changed every two days and the cells were passaged once reaching 
80% confluency. The cells were cultured under standard cell culture conditions (37°C, 
5% CO2). Passage 3-7 cells were used in all studies. 
3.2.2 Nanoparticle synthesis 
Gold nanoparticles with a diameter of 5 nm were synthesized via citrate reduction 
of tetrachloroauric (III) acid (HAuCl4) under reflux. Briefly, 100 mL of nanopure water 
was brought to boiling and 1 mL of 10 mg/mL HAuCl4 was added while stirring. After 1 
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minute, 1 mL of 10 mg/mL sodium citrate solution was added and allowed to stir for 1 
minute. Finally, 1 mL of 0.75 mg/mL of sodium borohyride in a 10 mg/mL sodium 
citrate solution was added and stirred for 5 minutes. The solution was then brought to 
room temperature. To promote aggregation of the particles, the gold nanoparticles were 
coated with poly-L-lysine (1-5 kD) by adding 16.57 µL of poly-L-lysine (3.33 x 10
-3
 M) 
per mL of nanoparticle solution and allowed to mix for 30 minutes. Poly-L-lysine 
hydrobromide (Sigma-Aldrich, St. Louis, MO) was dissolved in distilled water prior to 
use. 
3.2.3 Nanoparticle dissociation 
A dissociation study evaluating enzymatic degradation of the poly-L-lysine (PLL) 
linkages between nanoparticles was conducted. Nanoparticles were coated with PLL and 
incubated with 2.5% trypsin without EDTA. Sodium chloride (40 mM) was added to 
represent physiological conditions. The solutions were put on an orbital shaker and 
incubated at 37ºC for 72 hours. A microplate reader (BioTek) was used to obtain 
ultraviolet-visible spectroscopy measurements at various time points over the 72 hour 
time frame. At 72 hours, 10% FBS solution was added in order to evaluate if nanoparticle 
aggregation was affected due to adsorption of serum proteins. Nanoparticle morphology 
was evaluated using transmission electron microscopy (TEM). For TEM preparation, a 
drop of nanoparticle solution was placed on carbon coated copper 300 mesh grids 
(Electron Microscopy Sciences, Hatfield, Pa) which had been glow discharged. An FEI 
Tecnai transmission electron microscope fitted with a top mount AMT Advantage HR 
1kX1k digital camera and operating at 80 kV was used to visualize the grids.   
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3.2.4 MSC nanoparticle labeling 
Nanoparticle media was made by combining an equal volume of 5 nm PLL 
nanoparticles with 2x DMEM. MSCs were plated at a concentration of 5,000 cells/cm
2
 
and incubated with 5 nm citrate stabilized or 5 nm PLL media (200 µL/cm
2
) for 24 hours. 
Light microscopy was used to qualitatively analyze nanoparticle uptake by MSCs. 
Following nanoparticle incubation, the media was removed and the cells were washed 
with phosphate buffered saline (PBS) to remove excess particles. The cells were then 
incubated with 4',6-diamidino-2-phenylindole (DAPI) (1 µg/ml) for 15 minutes, followed 
by PBS washes. A Leica DMI2000B microscope, equipped with a Leica DFC290 
camera, was used to obtain phase contrast and dark field images. Controls consisted of 
cells not incubated with nanoparticles. 
Inductively coupled plasma mass spectrometry (ICP-MS) was used to 
quantitatively analyze nanoparticle uptake by MSCs. Following nanoparticle loading, the 
cells were collected using trypsinization and counted. To prepare the samples for ICP-
MS, all of the solutions were incubated in 300 µL of 70% nitric acid at 60ºC overnight. 
The solutions were then diluted to 3.7% nitric acid using ultrapure water prior to running 
the samples on the ICP-MS machine. Nanoparticle loading was quantified using a 
standard curve. Standard solutions were made by diluting AAS gold standard (Sigma-
Aldrich, St. Louis, MO) in the same background solution as the samples. The number of 
nanoparticles per cell was calculated based on the nanoparticle dimensions and cell 
number. 
For TEM analysis of nanoparticle endocytosis, MSCs were incubated with gold 
nanoparticle media for 24 hours. The cells were collected at various times points and 
fixed using glutaraldehyde/paraformaldehyde and osmium textroxide/potassium 
ferrocyanide fixatives. Cell pellets were embedded within an agar solution and 
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dehydrated by washing with serial concentrations of ethanol solutions, followed by 
treatment with 100% acetone. The pellets were then incubated in a sequential series of 
resin/acetone solutions and solidified in 100% resin at 60ºC for two days. The sample 
preparation process was accelerated using a microwave (Blowave, Pelco). The samples 
were then sectioned into 70 nm sections using an Ultracut UTC Ultramicrotome (Leica 
Microsystems, Wetzlar, Germany) and mounted onto thin bar mesh copper grids. The 
sections were post stained with lead citrate and viewed using a FEI Tecnai transmission 
electron microscope fitted with a top mount AMT Advantage HR 1kX1k digital camera 
and operating at 80 kV. 
3.2.5 Assessment of MSC function 
Cell viability was assessed following nanoparticle labeling using LIVE/DEAD 
viability staining and an MTS proliferation assay. LIVE/DEAD staining was performed 
by incubating the cells with a working solution of calcein AM (4 µm) and ethidium 
homodimer-1 (1 µm) for 45 minutes at 37ºC. The cells were washed with PBS and 
imaged using fluorescence microscopy (Leica DMI2000B microscope equipped with a 
Leica DFC 290 camera). 
A Sigma-Aldrich MTT Cell Proliferation Assay kit was used to perform the MTT 
assay. Briefly, MTT reagent was added to cells at a ratio of 100 µL/mL of media. The 
samples were incubated for 3 hours at 37°C. The detergent reagent was then used to lyse 
the cells. A universal microplate reader ELX800 (Bio-Tek Instruments Inc., Winooski, 
VT) was used to measure the absorbance values of the samples at 562 nm and a reference 
wavelength of 630 nm. Control cells consisted of cells not incubated with nanoparticles. 
A blank sample containing no cells was used and subtracted from all measurements. 
Cytotoxicity was assessed over a one week period at various time points. Triplicate 
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samples were used and the assay was performed twice. The number of cells was 
calculated using a standard curve. A one-way ANOVA, followed by t-tests for multiple 
comparisons, was used to statistically compare the experimental conditions to the control 
condition at the same time point (p<0.01). 
The ability of the cells to exhibit bipotent differentiation (i.e. adipogenic and 
osteogenic) after nanoparticle uptake was assessed for all nanoparticle conditions. 
Control cells consisted of cells not incubated with nanoparticles and which were induced 
to differentiate into the specified lineages. Negative control cells consisted of cells not 
incubated with nanoparticles and which were not induced to differentiate into the 
specified lineages.  
Briefly, adipogenesis was induced by plating cells at a density of 2.1 x 10
4
 
cells/cm
2
 and allowing the cells to grow to confluency. After the cultures reached 100% 
confluence, the growth media was replaced with adipogenic induction media (DMEM, 
10% FBS, 1% penicillin-streptomyocin, 1% glutamax, 1 µM dexamethasone (Sigma-
Aldrich, St. Louis, MO), 10 µg/mL 3-isobutyl-1-methylxanthine (Sigma-Aldrich, St. 
Louis, MO), 10 µg/mL insulin (Sigma-Aldrich, St. Louis, MO), and 100 µM 
indomethacin (Sigma-Aldrich, St. Louis, MO)). After three days, the adipogenic 
induction media was replaced with adipogenic maintenance media for one day (DMEM, 
10% FBS, 1% penicillin-streptomyocin, 1% glutamax, 10 µg/mL insulin). Three cycles 
of induction/maintenance were performed, after which the cells were incubated in 
adipogenic maintenance media for seven days. Control cells were supplemented only 
with adipogenic maintenance media. Oil red O (Sigma-Aldrich, St. Louis, MO) staining 
was used to assess adipogenesis. The cells were fixed in 10% formalin and then 
incubated in 60% isopropanol for 4 minutes. The cells were then incubated in oil red O 
staining solution for 5 minutes, rinsed in tap water, and counterstained in hematoxylin for 
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1 minute. After washing with tap water, the slides were mounted and viewed under phase 
contrast using a Leica DMI2000B microscope equipped with a Leica DFC290 camera. 
Osteogenesis was induced by plating cells at a density of 3.1 x 10
3
 cells/cm
2
. The 
cells were allowed to adhere for 24 hours, after which the media was replaced with 
osteogenic induction media (DMEM, 10% FBS, 1% pencillin-streptomyocin, 1% 
glutamax, 50 µg/mL ascorbic acid, 100 nM dexamethsone (Sigma-Aldrich, St. Louis, 
MO), and 10 mM beta-glycerophosphate disodium salt hydrate (Sigma-Aldrich, St. 
Louis, MO)). Osteogenesis was induced over a period of two weeks, after which a von 
Kossa staining kit (Fisher Scientific) was used to assess osteogenesis. The cells were 
fixed in 10% formalin and then incubated in 5% silver nitrate for 40 minutes with 
exposure to an ultraviolet light. The cells were washed in distilled water and then placed 
in 5% sodium thiosulfate for 2 minutes, after which they were rinsed in tap water and 
placed in nuclear fast red stain for 5 minutes. After washing with tap water, the slides 
were mounted and viewed under bright field using a Leica DMI2000B microscope 
equipped with a Leica DFC290 camera. 
3.2.6 Macrophage uptake of 5 nm nanoparticles 
Murine macrophages (J774A.1, ATCC) were cultured under standard cell culture 
conditions (37°C, 5% CO2) in DMEM with 10% FBS. The media was changed every two 
days and passaged once reaching confluency. Passage 10-20 cells were used in all 
studies. 
To assess cellular uptake of 5 nm nanoparticles by macrophages, the cells were 
plated at a concentration of 5,000 cells/cm
2
 and incubated with 5 nm nanoparticles, 5 nm 
PLL nanoparticles, and 5 nm PLL nanoparticles which had been incubated with trypsin 
(72 hours) to promote dissociation of the particles. After 24 hours, the nanoparticle media 
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was removed and the cells were imaged using a Leica DMI2000B microscope equipped 
with a Leica DFC290 camera. The cells were then collected using a cell scrapper and 
counted. The absorbance spectra of the cells were measured using a microplate reader 
(BioTek) and normalized to the cell number.  
3.2.7 MSC co-culture with macrophages 
MSCs were labeled with 5 nm PLL nanoparticles as described in Section 3.2.4. 
The MSCs were collected via trypsinization and washed two times with PBS to remove 
any nanoparticle debris. MSCs were then labeled with CellTracker
TM
 Green CMFDA dye 
(10 µM) (Life Technologies) for 40 minutes at 37ºC, washed with PBS, and plated at 
2,500 cells/cm
2
 in a 12 well plate. Macrophages were collected using a cell scrapper and 
fluorescently labeled with CellTracker
TM
 CM-DiI (Invitrogen). The cells were incubated 
with CM-DiI (5 µM) at 37ºC for 8 minutes and then 4ºC for 15 minutes, washed with 
PBS, and co-cultured with the MSCs at a concentration of 2,500 cells/cm
2
. The cells were 
imaged using a Leica DMI2000B microscope equipped with a Leica DFC290 camera 
3.3 RESULTS AND DISCUSSION 
3.3.1 In vitro dissociation of 5 nm nanoparticles 
The enzymatic dissociation of 5 nm PLL nanoparticle aggregates was investigated 
using trypsin digestion, which cleaves the carboxyl side of arginine and lysine. Initially 
following PLL coating and prior to trypsin incubation, the nanoparticles exhibited 
extensive peak broadening and red shifting in the absorbance spectra (Figure 3.2A). The 
spectrum underwent a substantial shift over 72 hours toward the original spectrum of the 
5 nm spheres, as quantified in Figure 3.2B and C. There was a slight discrepancy in the 
absorbance curves of the dissociated nanoparticles and the original 5 nm nanospheres, 
which could be attributed to the presence of some aggregates still present in solution. The 
 58 
stability of the dissociated nanoparticles was demonstrated by the lack of re-aggregation 
following addition of FBS to the solution. TEM images of the nanosphere solutions 
before PLL aggregation, after PLL aggregation, following enzymatic dissociation, and 
after addition of FBS are shown in Figures 3.2D-G. Following PLL addition, the 
nanoparticles form aggregates on the size range of hundreds of nanometers. However, 
after enzymatic dissociation, the nanoparticles form much smaller aggregates or return to 
the original 5 nm nanoparticles. 
3.3.2 Nanoparticle labeling and intracellular localization 
Endocytosis of 5 nm primary nanoparticles (citrate-stabilized) and 5 nm PLL 
nanoparticles by MSCs was evaluated using phase contrast and dark field microscopy 
(Figure 3.3). MSCs did not endocytose the 5 nm primary nanoparticles, which coincides 
with other reports in the literature of cells not readily endocytosing small nanoparticles 
(i.e. much smaller than 50 nm).  However, MSCs endocytosed the 5 nm PLL 
nanoparticles, which is most likely due to the larger size of the aggregated particles.  
TEM analysis of cell sections shows the nanoparticles compact and localized within 
endosomal compartments in the cell (Figure 3.4). It is possible that the nanoparticles 
formed clusters on the cell membrane and were subsequently endocytosed. However, it is 
also possible that the vesicles containing the endocytosed nanoparticles fused within the 
cells,
6
 resulting in the large number of nanoparticles per vesicle. TEM analysis of cell 
sections at 7 and 14 days show the nanoparticles are still localized in large, compact 
regions within the cell. Based on this analysis, it is difficult to distinguish if the 5 nm 
PLL nanoparticles are still aggregated or if they are dissociated into primary 
nanoparticles but still localized within close proximity to each other within the 
endosomal compartments. 
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Nanoparticle retention was quantified over 14 days using ICP-MS analysis. 
Figure 3.5A shows the average number of nanoparticles per cell, which decreases 
exponentially over time from approximately 5x10
7
 nanoparticles/cell to 5x10
6
 
nanoparticles/cell. Figure 3.5B compares the average number of nanoparticles/cell to the 
average total number of nanoparticles (both curves normalized to the day 1 data point). 
The curve representing the total number of nanoparticles decreases over time, suggesting 
that some nanoparticles are being lost due to exocytosis and not passed on to progeny. 
However, there is a  discrepancy between the two curves at the later time points, which 
can attributed to the nanoparticles being passed on to progeny following cell division. 
3.3.3 MSC function following labeling with 5 nm poly-L-lysine nanoparticles 
Stem cell function following labeling with 5 nm PLL nanoparticles was assessed 
over time using LIVE/DEAD staining and an MTT proliferation assay. MSCs remained 
viable (Figure 3.6A) and continued to proliferate (Figure 3.6B) following nanoparticle 
labeling. In addition, the ability of MSCs to differentiate to osteogenic and adipogenic 
lineages was also investigated. Oil red O staining was used to stain fatty lipid deposits red 
to assess adipogenesis and von Kossa staining was used to stain calcium deposits black to 
assess osteogenesis. MSCs retained their bipotent ability to differentiate to adipogenic 
and osteogenic lineages (Figure 3.6C). 
3.3.4 Macrophage interaction with 5 nm poly-L-lysine nanoparticles 
Macrophages were incubated with various formulations of 5 nm nanoparticles to 
investigate if macrophages will endocytose the particles following exocytosis by MSCs. 
The different nanoparticle conditions consisted of primary 5 nm nanoparticles (citrate-
stabilized), aggregated 5 nm nanoparticles (5 nm PLL), and aggregated 5 nm 
nanoparticles which were enzymatically dissociated (5 nm PLL dissociated). Figure 3.7A 
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shows dark field and bright field images of macrophages incubated with the various 
nanoparticle formulations. Macrophages were found not to endocytose 5 nm citrate-
stabilized nanoparticles. On the other hand, macrophages endocytosed 5 nm PLL 
nanoparticles to a large extent, most likely due to the aggregation of the nanoparticles and 
the PLL coating, which promotes cellular uptake. However, macrophages also 
endocytosed the 5 nm nanoparticles which were enzymatically dissociated. This could be 
attributed to the fact that the aggregated nanoparticles are not completely dissociated to 
individual 5 nm nanoparticles, as shown in Figure 3.2. As a result, there were still some 
nanoparticle aggregates which were large enough to be detected and endocytosed by 
macrophages. A more quantitative analysis of nanoparticle uptake by macrophages is 
shown in Figure 3.7B. UV-vis measurements confirm that macrophages did not 
endocytose 5 nm citrate-stabilized nanoparticles. In addition, macrophages incubated 
with 5 nm PLL and 5 nm PLL dissociated particles exhibited absorbance spectra 
indicative of nanoparticle uptake. The curves were normalized by the cell number and 
show a 1.5 fold difference in the peak absorbance; thus macrophages endocytosed the 
aggregated nanoparticles to a much larger extent compared to the dissociated 
nanoparticles. 
The 5 nm PLL nanoparticles were enzymatically dissociated using trypsin prior to 
incubation with macrophages. It is possible that the enzymatic dissociation using trypsin 
was not sufficient enough and not necessarily representative of the process occurring 
intracellularly within endosomes. Thus, in order to evaluate this, MSCs labeled with 5 nm 
PLL nanoparticles were co-cultured with macrophages. Prior to being cultured together, 
the cells were fluorescently labeled with CellTracker
TM
 Green CMFDA (MSCs) or 
CellTracker
TM
 CM-DiI (macrophages) in order to distinguish the two cell types within 
the culture. Dark field and bright field microscopy was used to qualitatively assess the 
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potential nanoparticle transfer from MSCs to macrophages. Fluorescence microscopy was 
used to identify the two cell types. The co-culture was evaluated daily, and by day 3 
nanoparticles were evident within macrophages, as shown by the yellow circles in Figure 
3.8. The nanoparticle uptake by macrophages can be attributed to nanoparticle exocytosis 
by MSCs followed by endocytosis of the nanoparticles by macrophages. However, it is 
also possible that macrophages endocytosed apoptotic MSCs containing nanoparticles. 
The percentage of stem cell death following therapeutic delivery is quite significant,
12,13
 
meaning that the possibility of infiltrating macrophages to scavenge apoptotic MSCs 
labeled with nanoparticles is very high. If this mechanism is occurring, then creating a 
dissociative nanoparticle system will not address this issue.  
3.4 CONCLUSIONS 
This study investigated the use of 5 nm nanoparticles as a potential labeling agent 
for tracking stem cells. The small size of the nanoparticles was thought to be an 
advantage in terms of evading transfer to non-stem cells. The nanoparticles were 
demonstrated to be safe and non-toxic to MSCs. In vitro dissociation studies 
demonstrated that the aggregated 5 nm PLL nanoparticles could be enzymatically 
dissociated over time, but nanoparticles were still found to be transferred to macrophages 
in co-culture experiments. While this transfer to macrophages could partially be 
attributed to the incomplete dissociation of the aggregated nanoparticles to primary 5 nm 
particles, it is also likely that macrophages were endocytosing apoptotic MSCs labeled 
with nanoparticles. As a result, it was concluded that the 5 nm PLL nanoparticle system 
did not address the issues of ensuring that contrast agent is not transferred to surrounding 
cells and that only MSCs are being monitored in vivo. Therefore, a dual nanoparticle 
system was developed, as outlined in Chapter 4, which is capable of tracking stem cells 
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following delivery in vivo and also monitoring macrophage infiltration and potentially the 
transfer of contrast agents from stem cells to macrophages. 
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Figure 3.1:  Urine excretion (blue curve) and carcass retention (red curve) of quantum 
dots of various hydrodynamic diameters 4 hours after intravenous injection. 
Reprinted with permission from Choi et al.
1
 Copyright 2007 Nature 
Publishing Company. 
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Figure 3.2: (A) Ultraviolet-visible spectroscopy of 5 nm PLL nanoparticles over time 
with trypsin incubation and quantification of (B) peak shifting and (C) peak 
broadening. Transmission electron microscopy images of (D) 5 nm citrate-
stabilized nanoparticles, (E) 5 nm PLL coated nanoparticles at T0, (F) 5 nm 
PLL coated nanoparticles 72 hours following trypsin incubation, and (G) 5 
nm PLL coated nanoparticles 72 hours following trypsin incubation with 
addition of 10% FBS. Scale bar = 100 nm.  Abbreviations: fetal bovine 
serum (FBS), nanoparticles (NPs), poly-L-lysine (PLL). 
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Figure 3.3:  Dark field/DAPI overlay and phase contrast images of control cells (no 
nanoparticles) and cells incubated with 5 nm citrate-stabilized and 5 nm 
poly-L-lysine nanoparticles. Scale bar = 100 µm. Abbreviations: citrate-
stabilized (CS), poly-L-lysine (PLL). 
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Figure 3.4:  TEM images of 70 nm sections of MSCs (A) 24 hours after loading, 
(B) 7 days after loading, and (C) 14 days after loading with 5 nm 
poly-L-lysine nanoparticles. Scale bar = 1 µm. Inset scale bar = 500 
nm. 
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Figure 3.5:  (A) Average concentration of nanoparticle loading and retention over a 
two week time period using inductively coupled plasma mass 
spectrometry.  Error bars indicate standard deviation. (B) Average 
nanoparticle concentration compared to the total average number of 
nanoparticles over time. Error bars indicate standard deviation. 
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Figure 3.6:  (A) LIVE/DEAD images of cells over a one week time period. Scale 
bars = 100 µm. (B) Cell proliferation over a one week  time period was 
examined using an MTT cell proliferation assay. Error bars indicate 
standard deviation. (C) Bright field images of cells induced to 
differentiate to adipogenic and osteogenic lineages. Adipogenesis was 
assessed using oil red O staining and osteogenesis was assessed using 
von Kossa staining. Scale bars = 100 µm.  
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Figure 3.7:  (A) Dark field and bright field microscope images of macrophages incubated 
with various formulations of 5 nm nanoparticles and (B) the corresponding 
optical absorbance spectra.  Scale bar = 100 µm. Abbreviations: citrate-
stabilized (CS), poly-L-lysine (PLL).  
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Figure 3.8:  Dark field, bright field, and fluorescent microscope images of nanoparticle 
labeled MSCs co-cultured with macrophages. Scale bar = 100 µm. 
Abbreviations: poly-L-lysine (PLL). 
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Chapter 4: Optimization of a dual nanoparticle system for in vivo 
monitoring of mesenchymal stem cells and macrophages 
4.1 INTRODUCTION 
Stem cell therapy shows great potential to treat a large variety of diseases, 
including cardiovascular diseases, which are the number one cause of death globally.
1
 In 
particular, bone-marrow-derived mesenchymal stem cells (MSCs) are advantageous in 
that they possess angiogenic properties, are easily obtained in large numbers and 
expandable in culture, and are part of the ischemic response.
1
 Numerous preclinical and 
clinical trials have investigated the therapeutic benefits of stem cell therapy for 
cardiovascular diseases. However, advances in the field of stem cell therapy have been 
limited by the inability to track administered cells,
2
 which would provide information 
concerning cell engraftment and persistence, mechanisms of vascular regeneration, and 
the role of MSCs in vascular repair.  
Conventional methods for assessing the biological mechanisms underlying 
disease states and potential therapies rely on postmortem histology, which only offers 
endpoint measurements and requires a large number of animals to be sacrificed in order 
to produce statistically significant results. A more ideal cell tracking method would 
involve using noninvasive longitudinal imaging to monitor cells. Towards this end, many 
contrast agents are currently being investigated to label cells for cell tracking purposes, 
including reporter genes,
3-6
 radionuclides,
6-8
 fluorescent probes,
9-11
 and nanoparticles
4,8,12-
14
. Nanoparticles, such as quantum dots, iron oxide nanoparticles, and plasmonic 
nanoparticles (gold and silver), offer many advantages over other contrast agents. For 
example, nanoparticles can be optimized to promote cellular uptake through shape, size, 
and surface coating modification
12,15-19
 and allow for long-term monitoring of cells
12-14,20
. 
However, viable and non-viable cells cannot be distinguished using nanoparticle contrast 
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agents. As a result, it is not possible to detect if a cell is dead and has been endocytosed 
by macrophages, leading to a transfer of contrast agent from the labeled cells to 
macrophages. Other investigators have found nanoparticle transfer to macrophages,
4,21,22
 
resulting in the monitoring and tracking of macrophages instead of the stem cell therapy. 
Thus, the goal of this study is to develop a nanoparticle system which is capable 
of tracking stem cells following delivery in vivo and also monitoring macrophage 
infiltration. Macrophages are known to have key roles in wound healing and vascular 
regeneration
23-26
 and to be influenced by and exert paracrine effects on stem cells, 
including MSCs
27-29
. The nanoparticle system will consist of gold plasmonic 
nanoparticles. Gold nanoparticles can be synthesized in various shapes and sizes and their 
absorption characteristics can be tuned to maximally absorb in the near-infrared region, 
where the absorption from endogenous tissue is the lowest. Gold nanoparticles are also 
non-toxic to cells in certain formulations
12,30,31
 and exhibit surface plasmon resonance, 
which contributes to their superior optical absorption properties,
32,33
 making them ideal 
contrast agents for photoacoustic imaging
20,34
. Figure 4.1 shows the outline of the dual 
nanoparticle system consisting of gold nanorods to label MSCs and gold nanospheres to 
label macrophages. This system is delivered within a 3D PEGylated fibrin gel, which 
promotes the angiogenic potential of MSCs and leads to tubular network formation 
within the gels, as demonstrated by previous work in our lab.
35
 The gold nanorods were 
selected because these particles maximally absorb in the near-infrared region. On the 
other hand, gold nanospheres maximally absorb in the visible light region (520 nm), but 
plasmon coupling following nanosphere endocytosis by cells leads to peak broadening. 
Thus, the gold nanospheres will only be detected using photoacoustic imaging when they 
are endocytosed by macrophages and imaged within the tissue optical window of 650-
1000 nm. To evaluate this nanoparticle system, various in vitro assays were performed, 
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including labeling of cells with the nanoparticles and the assessment of cell function and 
viability following nanoparticle labeling. In addition, in vitro and in vivo photoacoustic 
imaging experiments were performed to assess the feasibility of monitoring the two cell 
types. Histological analysis and mass spectrometry were also performed to verify the in 
vivo photoacoustic imaging results. This study has important implications for cell 
tracking and the role of MSCs and macrophages in vascular regeneration. 
4.2 MATERIALS AND METHODS 
4.2.1 Cell culture 
Rat mesenchymal stem cells were isolated from the bone marrow of Lewis rats 
(200-300 g). The femoral marrow cavity was flushed and adherent cells were collected 
and cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS), 1% glutamax, and 1% penicillin-
streptomyocin. Non-adherent cells were removed after 24 hours by replacing the media. 
The media was then changed every two days and the cells were passed once reaching 
80% confluency. The cells were cultured under standard cell culture conditions (37°C, 
5% CO2). Passage 3-7 cells were used in all studies. 
Murine macrophages (J774A.1, ATCC) were cultured under standard cell culture 
conditions (37°C, 5% CO2) in DMEM with 10% FBS. The media was changed every two 
days and passaged once reaching 80% confluency. Passage 10-20 cells were used in all 
studies. 
4.2.2 Nanoparticle synthesis 
Spherical gold nanoparticle seeds (20 nm in diameter) were synthesized by 
heating 100 mL of distilled (DI) water to 100°C and adding 1 mL of 10 mg/mL gold(III) 
chloride hydrate (HAuCl4). Then, 5 mL of 10 mg/mL sodium citrate dissolved in DI 
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water was added and the reaction was allowed to cool to room temperature. Gold 
nanoparticles 50 nm in diameter were synthesized by mixing 7.5 mL of 10 mg/mL 
HAuCl4, 15.61 mL of 0.2 M ammonium hydroxylamine, 750 mL of DI water, and 50 nm 
of seed solution while stirring. The surface of the gold nanoparticles was coated with 
methoxy-polyethylene glycol-thiol (mPEG-SH) at a concentration of 0.1 mM and 
allowed to react for 30 minutes on a shaker, followed by centrifugal filtration (Amicon 
ultra-15, Millipore) to remove residual PEG. 
Gold nanorods (NRs) were synthesized via seed mediated growth as previously 
described.
36,37
 Briefly, the seed solution was synthesized by mixing 5 mL of cetyl 
trimethylammonium bromide (CTAB) (0.2 M) with 5 mL of HAuCl4 (0.5 mM) while 
stirring vigorously. Then 0.6 mL of ice cold sodium borohydride (NaBH4) was added to 
the solution. The growth solution was prepared by mixing 380 mL of 0.2 M CTAB, 8 mL 
of 0.01 M silver nitrate (AgNO3), and 40 mL of 0.01 M HAuCl4 while stirring at 30°C. 
Then 4.4 mL of 0.1 M ascorbic acid (C6H8O6) was added drop wise, resulting in a color 
change from yellow to colorless. To produce NRs, 0.958 mL of gold nanoseeds were 
added to the growth solution and allowed to stir for 3 minutes. The solution was allowed 
to age overnight, centrifuged twice at 14000 rcf for 45 minutes, and resuspended in 
ultrafiltrated (18 MΩcm, Thermo Scientific Barnstead Diamond water purification 
systems) deionized water. 
The NR surface was modified by replacing CTAB with mPEG-SH through ligand 
exchange. Briefly, an equal volume of mPEG-SH (0.2 mM) was added to the gold NR 
solution, sonicated for 1 minute, and allowed to react overnight. Excess PEG was 
removed by centrifugal filtration (Amicon ultra-15, Millipore) at 2000 rcf for 10 minutes. 
Finally, a layer of silica was deposited on the surface of the PEG modified NRs through a 
modified Stöber method, as previously described.
38-40
 Under vigorous stirring, 2 mL of 
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PEGylated NRs was added to 3 mL of isopropanol, followed by 1.2 mL of tetraethyl 
orthosilica (TEOS) (3%) in isopropanol and 1.2 mL of ammonium hydroxide (8.4%) in 
isopropanol. The reaction was allowed to mix for 2 hours, followed by centrifugal 
filtration at 500 rcf for 15 minutes, twice. The NRs were then coated with a layer of poly-
L-lysine (5 kD; Sigma-Aldrich) at a concentration of 0.833 mM and allowed to react for 
2 hours, followed by centrifugation at 3000 rcf for 10 minutes and then 5000 rcf for 7 
minutes. 
The size of the nanoparticles was characterized using transmission electron 
microscope (TEM) analysis and dynamic light scattering (DLS), and the surface charge 
was characterized using zeta potential measurements. For TEM preparation, a drop of 
nanoparticle solution was placed on carbon coated copper 300 mesh grids (Electron 
Microscopy Sciences, Hatfield, Pa) which had been glow discharged. An FEI Tecnai 
transmission electron microscope fitted with a top mount AMT Advantage HR 1kX1k 
digital camera and operating at 80 kV was used to assess NR size and morphology. 
Chemical analysis of the silica coating on the NR surface was performed by imaging the 
grids using the TEM mode of a Hitachi S5500 FESEM operated at 30 kV and equipped 
with an energy dispersive spectrometer (EDS). ImageJ analysis was used to quantify the 
size of the NRs and thickness of the silica coating (n = 100). A DelsaNano (Beckman 
Coulter, Inc., Brea, CA) was used for DLS analysis of spherical nanoparticles. 
Nanoparticle solutions were loaded into a cuvette and readings were taken at a 
temperature of 25°C. For size measurements, 5 repetitions were performed for each 
nanoparticle solution with 60 readings per repetition. A Zetasizer Nano ZS (Malvern) 
was used to measure the zeta potential of nanoparticle solutions. A total of 3 
measurements, with 15 repetitions, were collected at a temperature of 25°C. 
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4.2.3 Nanoparticle labeling of cells 
Gold nanosphere media was made following PEGylation of 50 nm nanospheres. 
The nanospheres were sterile filtered using a 0.22 µm filter, centrifuged in a centrifugal 
filter tube (Amicon ultra-15, Millipore) at 3000 rcf for 5 minutes, and resuspended in cell 
culture media at a concentration of approximately 10
12
 NPs/mL. Gold NR  media was 
made following PLL coating of silica NRs. The NRs were sterile filtered using a 0.22 µm 
filter and centrifuged at 3000 rcf for 10 minutes. The supernatant was then centrifuged at 
5000 rcf for 7 minutes. The NRs were resuspended in cell culture media at a 
concentration of approximately 10
12
 NRs/mL. Macrophages were incubated with 
nanosphere media (200 µL/cm
2
) and MSCs were incubated with NR media (200 µL/cm
2
) 
for 24 hours. 
Bright field and dark field microscopy was used to qualitatively analyze 
nanoparticle uptake by macrophages and MSCs. Following nanoparticle incubation, the 
media was removed and the cells were washed with phosphate buffered saline (PBS) to 
remove excess particles. The cells were then incubated with DAPI (1 µg/ml) for 15 
minutes, followed by PBS washes. A Leica DMI2000B microscope, equipped with a 
Leica DFC290 camera, was used to obtain bright field and dark field images. Controls 
consisted of cells not incubated with nanoparticles. 
Inductively coupled plasma mass spectrometry (ICP-MS) was used to 
quantitatively analyze nanoparticle uptake by macrophages and MSCs in 2D, as well as 
by macrophages in 3D PEGylated fibrin gels. The PEGylated fibrin gels were 
synthesized as described below and contained 50,000 cells/mL and 10
12
 NPs/mL. 
Following nanoparticle loading in 2D, the cells were collected using trypsinization and 
counted. To collect the cells in 3D, the gels were digested by incubation with 500 µL of 
bovine pancreatic trypsin (5 mg/mL in 0.9% sodium chloride) per 1 mL of gel for 1 hour. 
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The reaction was quenched with serum containing media and the solution was filtered 
with a 70 µm and 40 µm cell strainer and centrifuged at 600 rcf for 7 minutes to collect 
the cells. To prepare the samples for ICP-MS, all of the solutions were incubated in 300 
µL of 70% nitric acid at 60ºC overnight. The solutions were then diluted to 3.7% nitric 
acid using ultrapure water prior to running the samples on the ICP-MS machine. The 
samples containing MSCs incubated with 50 nm gold nanospheres were prepared for 
ICP-MS analysis by heating the samples at 150ºC and bringing them to dryness. The 
samples were then resuspended in 200 µL of aqua regia and further diluted with 2% HCl. 
Nanoparticle loading was quantified using a standard curve. Standard solutions were 
made by diluting AAS gold standard (Sigma-Aldrich, St. Louis, MO) in the same 
background solution as the samples. The number of nanoparticles per cell was calculated 
based on the nanoparticle dimensions and cell number. 
For TEM analysis of nanoparticle endocytosis, MSCs were incubated with gold 
NR media for 24 hours. The cells were collected and fixed using 
glutaraldehyde/paraformaldehyde and osmium textroxide/potassium ferrocyanide 
fixatives. Cell pellets were embedded within an agar solution and dehydrated by washing 
with serial concentrations of ethanol solutions, followed by treatment with 100% acetone. 
The pellets were then incubated in a sequential series of resin/acetone solutions and 
solidified in 100% resin at 60ºC for two days. The sample preparation process was 
accelerated using a microwave (Blowave, Pelco). The samples were then sectioned into 
70 nm sections using an Ultracut UTC Ultramicrotome (Leica Microsystems, Wetzlar, 
Germany) and mounted onto thin bar mesh copper grids. The sections were post stained 
with lead citrate and viewed using a FEI Tecnai transmission electron microscope fitted 
with a top mount AMT Advantage HR 1kX1k digital camera and operating at 80 kV. 
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MSCs and macrophages were co-cultured in a 3D PEGylated fibrin gel to 
investigate the nanoparticle system in a 3D environment. PEGylated fibrin gels were 
synthesized as described below and contained 25,000 MSCs/mL; 50,000 
macrophages/mL; and 10
14
 NPs/mL. The gels were made in 12 well transwell plates with 
8.0 µm pore sizes and were incubated at 37°C in MSC growth media. 
4.2.4 Stability of nanorod silica coating 
The stability of the silica coating on the nanorods following MSC endocytosis 
was evaluated using TEM and EDS analysis. MSCs were labeled with silica NRs and 
collected immediately. In order to collect the endocytosed NRs, the cells were then lysed 
with RIPA buffer (Santa Cruz Biotechnology) supplemented with PMSF, protease 
inhibitor cocktail, and sodium orthovanadate. The samples were incubated in lysis buffer 
for 30 minutes and homogenized by passing the samples through a 21G needle ten times 
at 4ºC. The samples were then centrifuged at 3200 x g for 10 minutes and the supernatant 
collected. The samples were washed with water and centrifuged again to concentrate the 
nanorods (3200 x g for 10 minutes). A drop of nanoparticle solution was then placed on 
carbon coated copper 300 mesh grids (Electron Microscopy Sciences, Hatfield, Pa) which 
had been glow discharged. Control conditions consisted of silica NRs exposed to the 
RIPA lysis buffer and silica NRs which were not exposed to the RIPA lysis buffer. The 
grids were then imaged using the TEM mode of a Hitachi S5500 FESEM operating at 30 
kV and equipped with an energy dispersive spectrometer (EDS). 
4.2.5 Cell viability 
Cell viability was assessed following nanoparticle labeling using LIVE/DEAD 
viability staining and an MTS proliferation assay. LIVE/DEAD staining was performed 
by incubating the cells with a working solution of calcein AM (4 µm) and ethidium 
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homodimer-1 (1 µm) for 45 minutes at 37ºC. The cells were washed with PBS and 
imaged using fluorescence microscopy (Leica DMI2000B microscope equipped with a 
Leica DFC 290 camera). 
Cell proliferation following nanoparticle labeling was assessed using MTS. Cells 
were incubated with DMEM media containing 20% MTS solution for 4 hours at 37ºC. 
The supernatant was collected and the absorbance value measured at 490 nm (n=3). A 
blank sample containing no cells was subtracted from all measurements. 
The maintenance of cell function in 3D PEGylated fibrin gels was assessed after 
laser irradiation by examining cell morphology and tubular network formation. 
Difunctional succinimidyl glutarate PEG (8 mg/mL in PBS without calcium; NOF 
America) was added to fibrinogen (80 mg/mL in PBS without calcium; Sigma) in a 1:1 
volume ratio, and the reaction was allowed to take place at room temperature for 3-5 
minutes. An equal volume of MSCs as the fibrinogen and PEG mixture was then added at 
a concentration of 200,000 cells/mL. Gels with either NR labeled MSCs or unlabeled 
MSCs were made. The reaction then underwent gelation by adding an equal volume 
solution of thrombin (25 U/mL in 40 mM CaCl2; CalBiochem). The final concentrations 
in the gel were 10 mg/mL of fibrinogen; 1 mg/mL of SG-PEG-SG; 50,000 cells/mL; and 
12.5 U/mL of thrombin. The gels were made in 4 well chambered coverglass slides 
(Laboratory-Tek II; Nalge Nunc) and incubated at 37°C in MSC growth media. 
The gels were irradiated at various time points (day 1, 4, and 7) using a 800 nm 
laser with a fluence of 10 mJ/cm
2
 for 100 pulses. Control conditions consisted of the 
same gel formulations without laser irradiation. At day 7, the cells were stained with 
calcein AM (10 µM) and 3D z-stacks were taken using a Leica SP2 AOBS confocal 
microscope (10x magnification; 512x512 resolution). The images covered approximately 
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1 mm with a step size of approximately 3 µm. The 3D images were reconstructed using 
ImageJ. 
4.2.6 In vitro photoacoustic imaging 
A tissue mimicking phantom with varying ratios of NR labeled MSCs and 
nanosphere labeled macrophages was prepared for combined ultrasound and 
photoacoustic (US/PA) imaging. The bottom layer of the phantom consisted of gelatin 
(8% by weight; Sigma-Aldrich) with 15 µm diameter silica particles (0.2% by weight; 
Sigma-Aldrich) for ultrasonic scattering. The cell inclusions (20 µL) were placed on top 
of the bottom layer and consisted of gelatin mixed with cells. Each cell inclusion had a 
total of 10,000 cells. 
Photoacoustic signals were captured using the Vevo LAZR system (VisualSonics, 
Inc.) including a tunable laser as well as a 40 MHz array transducer combined with an 
optical fiber bundle to deliver the laser pulses. RF signals were acquired for laser 
wavelengths ranging from 680-970 nm and with a laser fluence of 5-15 mJ/cm
2
. The 
transducer was mechanically scanned along the tissue mimicking phantom to obtain 3D 
photoacoustic information. The signals exported from the imaging system were post-
processed for beamforming, laser fluence compensation, image reconstruction, and signal 
quantification. For spectral analysis, the quantified photoacoustic signals were used to 
calculate the ratio of the NR labeled MSCs and the nanosphere labeled macrophages in 
each voxel by comparison to weighted sums of their optical absorption spectrum. Then, 
the estimated ratios in the voxels were averaged to calculate the overall cell ratio for 
whole inclusions. 
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4.2.7 Ischemic injury and in vivo photoacoustic imaging 
Animal handling and care followed the recommendations of the National 
Institutes of Health (NIH) guidelines for the care and use of laboratory animals. All 
protocols were approved by the Animal Care Committee at the University of Texas at 
Austin. Lewis rats (11 weeks) weighing 250-300 g were used. Rats were anesthetized 
using isoflurane (0.5-2%) infused with oxygen (2 L/min). A femoral artery ligation was 
performed in Lewis rats (11 weeks, male) to induce hind limb ischemia. Through a small 
incision on the medial side of the thigh, the femoral artery of a single hind limb was 
separated from the nearby nerve and vein and ligated immediately distal to the inferior 
epigastric artery and proximal to the branch point of the popliteal and saphenous arteries 
using Prolene 5-0 sutures. The ligated segment was then excised and the skin incision 
closed with interrupted sutures. The animal was allowed to recover overnight and the 
following day (about 24 hours later), MSCs were injected intramuscularly into the 
gastrocnemius muscle of the ligated limb. PEGylated fibrin injections were prepared by 
combining difunctional succinimidyl glutarate PEG (4 mg/mL in PBS without calcium; 
NOF America) to fibrinogen (40 mg/mL in PBS without calcium; Sigma) in a 1:1 volume 
ratio. An equal volume of MSCs labeled with gold NRs was mixed with the PEGylated 
fibrinogen solution in a 1:1 volume ratio at a concentration of 13x10
6
 cells/mL. Next, 50 
nm PEGylated gold nanospheres was added to the cell/PEGylated fibrin solution at a 
concentration of 10
14
 NPs/mL. The solution was then loaded into a 23 G needle syringe, 
followed by an equal volume of thrombin (25 U/mL in 40 mM CaCl2). The solution was 
mixed thoroughly within the syringe and the gel solution (300 uL) was injected into the 
gastrocnemius of the rat.  The final concentrations in the gel were 5 mg/mL of fibrinogen; 
0.5 mg/mL of SG-PEG-SG; 3.33x10
6
 cells/mL; and 12.5 U/mL of thrombin. Prior to 
delivery, MSCs were fluorescently labeled with CellTracker
TM
 CM-DiI (Invitrogen). The 
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cells were incubated with CM-DiI (15 µM) at 37ºC for 8 minutes and then 4ºC for 15 
minutes, washed with PBS, and resuspended in DMEM. 
Ultrasound and photoacoustic signals were captured using the Vevo LAZR 
(VisualSonics, Inc.) system. A 40 MHz array transducer incorporated with a fiber bundle 
was submerged in a water bath, and the rat hind limb was coupled through a transparent 
film at the bottom of the water bath. RF signals were acquired for laser wavelengths 
ranging from 680-970 nm and with a laser fluence of 5-10 mJ/cm
2
. Post-processing was 
the same as that for the in vitro photoacoustic. The processed photoacoustic and 
spectroscopic images were overlaid with ultrasound images using a user-defined 
threshold of the photoacoustic signals. 
4.2.8 Histology 
At the terminal endpoint of the study, animals were sacrificed and the 
gastrocnemius muscles were isolated, embedded in optimal cutting temperature (OCT) 
compound, submerged in liquid nitrogen-cooled isopentane, and stored at -80ºC until 
further processing. The samples were cut into 12 µm thick sections using a cryostat and 
placed onto positively charged microscope slides. The tissue sections were fixed in 10% 
formalin for 15 minutes. Imunohistochemical and histochemical staining were 
subsequently performed. 
For immunostaining, the slides were incubated in 0.125% trypsin solution for 20 
minutes at 37ºC. They were then permeabilized in 0.5% Triton X-100 in TBST for 30 
minutes and blocked in 10% normal goat serum for 1 hour. The slides were incubated 
overnight at 4ºC in the primary antibody (1:50 dilution in 2.5% normal goat serum) 
(ED1; Millipore), followed by incubation with a fluorescence-conjugated secondary 
antibody (1:200 in 2.5% normal goat serum) (Alexa Fluor 488 Goat Anti-Mouse 
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Immunoglobulin G; Life Technologies). As a negative control, normal immunoglobulin 
G was used instead of the primary antibody. The samples were counterstained with DAPI 
(5 ug/mL) for 15 minutes, mounted, and viewed using a fluorescence microscope 
(DMI2000B; Leica) 
TUNEL staining was performed with the APO-BrdU TUNEL Assay Kit 
(Invitrogen). The slides were incubated in 0.125% trypsin for 20 minutes at 37ºC, 
followed by permeabilization in 0.5% Triton X-100 for 30 minutes. The slides were then 
incubated with TdT and BrdUTP for 2 hours at 37ºC. Alexa Fluor 488 dye-labeled anti-
BrdU antibody was applied for 30 minutes. The slides were then counterstained with 
DAPI (5 ug/mL) for 15 minutes, mounted, and viewed using a fluorescence microscope 
(DMI2000B; Leica). 
4.2.9 Fluorescence-activated cell sorting of macrophages 
Seven days following intramuscular injection of nanorod labeled or unlabeled 
MSCs and nanospheres within PEGylated fibrin, animals were sacrificed and the 
gastrocnemius muscle was isolated. The muscle samples were finely minced and 
incubated in 1% collagenase in DMEM for 1 hour at 37ºC under constant agitation. 
Samples were then filtered through cell strainers (40 µm and 70 µm), washed with PBS, 
and blocked for 30 minutes in fluorescence-activated cell sorting (FACS) buffer (1% 
BSA in PBS + 1% sodium azide). Samples were then incubated with primary antibody 
(1:50; ED1; Millipore) in FACS buffer for 45 minutes, washed, and incubated in 
secondary antibody (1:50; Alexa Fluor 488 Goat Anti-Mouse Immunoglobulin G; Life 
Technologies) for 45 minutes. Next, samples were fixed in 4% neutral buffered formalin 
for 15 minutes, washed, and resuspended in PBS. Samples were then sorted for 
macrophages using a FACSAria flow cytometer. Following sorting, samples were 
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digested for ICP-MS analysis. The cells were collected by centrifuging at 270 x g for 5 
minutes and resuspended in a small volume of aqua regia solution. The samples were 
heated at 150ºC and brought to dryness. They were then resuspended in 250 µL of aqua 
regia and further diluted with ultrapure water to give an HCl concentration of 5%. A 
standard curve was used to quantify the amount of gold in the cells by diluting AAS gold 
standard (Sigma-Aldrich, St. Louis, MO) in the same background solution as that of the 
cell solutions. The data was quantified by calculating the mass of gold per macrophage. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Nanoparticle characterization 
The size, shape, and surface charge of gold NRs and nanospheres were 
characterized using ultraviolet-light spectroscopy (UV-vis), TEM analysis, DLS, and zeta 
potential measurements. The absorbance spectra of gold NRs had a peak around 750 nm, 
which red shifted 20 nm following silica coating and an additional 8 nm following poly-
L-lysine (PLL) coating (Figure 4.2A). Zeta potential measurements confirmed the 
sequential coatings were deposited on the NRs (Figure 4.2A), as the surface charge was 
+40 mV for CTAB coated NRs, -0.61 mV for PEG coated NRs, -30.37 mV for silica 
coated NRs, and +26 mV for PLL coated NRs. Using TEM analysis, the size of the NRs 
was measured as 55.63 ± 9.14 x 15.59 ± 3.45 nm, with a silica coating thickness of 25.04 
± 3.06 nm (Figure 4.2A). Energy dispersive spectrometry (EDS) confirmed silica coating 
of the gold nanorods (Figure 4.3). The 50 nm spherical nanoparticles had an absorbance 
peak around 520 nm (Figure 4.2B), with a red shift of a few nm following PEG coating. 
TEM analysis confirmed the spherical shape of the particles and DLS measured the 
hydrodynamic diameter of the particles as being 50.4 nm with a polydispersity index of 
0.044 (Figure 4.2B). Zeta potential measurements demonstrated that the nanospheres had 
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a negative surface charge (-46.07 mV), which became closer to neutral (-8.41 mV) 
following PEG coating (Figure 4.2B). 
4.3.2 Nanoparticle labeling of cells 
MSCs were incubated with PLL silica NRs and the uptake by the cells was 
qualitatively analyzed using microscopy and quantitatively analyzed using ICP-MS. Dark 
field microscopy demonstrated nanoparticle labeling of MSCs as evident by the 
yellow/green color of the cells as compared to control cells (Figure 4.4A, C). In addition, 
dark nanoparticle aggregates within cells were visible under bright field (Figure 4.4B, D). 
Figure 4.5 shows TEM images of MSCs incubated with nanorods and verifies the 
nanorods were endocytosed by the cells and are localized within endosomal 
compartments. Others have seen similar endocytosis and packaging of gold nanoparticles 
within stem cells.
30
 ICP-MS analysis quantified the number of nanorods per MSC as 1.89 
± 0.877 x 10
5 
nanorods/cell (Figure 4.6A). This large extent of extent of cellular uptake 
of the nanorods can be attributed in part to both the silica coating, providing a more 
spherical shape to the particle which is more conducive for cellular uptake,
16,17,41
 and the 
PLL surface coating, which is commonly used as a transfection agent and has been used 
to promote cellular uptake of iron oxide nanoparticles
42-44
. 
Macrophages were incubated with 50 nm PEGylated gold nanospheres and dark 
field and bright field microscopy demonstrated a large extent of uptake by the cells 
(Figure 4.4G, H) as compared to control cells (Figure 4.4E, F). In addition, MSCs were 
incubated with the same nanoparticles and there was no evident uptake by the cells 
(Figure 4.4I, J), which was verified by ICP-MS measurements (Figure 4.6B). The reason 
MSCs did not uptake these particles can be attributed to the PEG surface coating, which 
passivates the particles and gives them a neutral charge, leading to minimal detection and 
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uptake by cells.
41,45
 Macrophages, on the other hand, are characterized by their high rate 
of nonspecific uptake, and thus endocytose these particles to a large extent.
46
 Over time 
the mPEG-SH layer is slowly displaced by serum proteins, leading to preferential uptake 
by macrophages.
47,48
 Thus, 50 nm PEGylated gold nanospheres can be used as a contrast 
agent to preferentially label macrophages and identify the infiltration of macrophages in 
vivo. ICP-MS measurements quantified the number of gold nanospheres per macrophage 
as 6.76 ± 1.68 x 10
3
 nanospheres/cell in 2D culture (Figure 4.6B). The macrophages were 
also cultured in 3D PEGylated fibrin gels containing gold nanospheres in order to more 
closely resemble the in vivo scenario in which macrophages will infiltrate the ischemic 
area and come in contact with nanospheres delivered within a 3D hydrogel. The number 
of gold nanospheres per macrophage in 3D culture as measured with ICP-MS was 4.38 ± 
1.63 x 10
3
 nanospheres/cell. These measurements took into account the fact that gold 
nanospheres not endocytosed by cells could still be entrapped in the gels. As a result, gels 
containing only gold nanospheres were used as a blank and subtracted from the 3D cell 
measurements. 
 Co-culture of the MSCs and macrophages within a 3D PEGylated fibrin gel 
showed that nanorod labeled MSCs formed tubular networks in the gels after 7 days. 
Macrophages maintained a rounded morphology within the gel and started to endocytose 
nanoparticles. Figure 3.7 shows the co-culture system, with nanoparticle labeled 
macrophages circled in yellow. 
4.3.3 Stability of nanorod silica coating 
TEM analysis of MSCs which had endocytosed NRs suggested that the silica 
coating on the NR was no longer present. In addition, the peak broadening of the UV-vis 
spectra of cells labeled with NRs also supported this claim. As a result, a study was 
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conducted to confirm if the silica coating was still present on the NRs following 
endocytosis. It is a possibility that the silica coating was not visible in the TEM  images 
because the electron density of silica is approximately the same as the resin in which the 
cells were embedded for sectioning.
49
 To overcome this issue, the cells were lysed 
following NR endocytosis and the particles were separated out of solution and imaged on 
a TEM grid. EDS analysis was performed to chemically analyze the particles and the 
presence of silicon on the outer surface. Figure 4.8A and 4.8B show the TEM and EDS 
analysis, respectively, of silica NRs. The EDS analysis shows gold in green and the 
silicon in red, and the quantitative analysis indicates a large peak representing silicon. On 
the other hand, NRs which were isolated following MSC endocytosis (Figure 4.8D-F) 
show many NRs without the presence of a silica layer and there appears to be dispersed 
silica in the background. Also, quantitative analysis shows a dramatic decline in the 
silicon peak. To confirm the buffer solution used to lyse the cells did not affect the NRs, 
silica NRs which were incubated with the lysis buffer solution were also evaluated 
(Figure 4.8G-I). The results demonstrate that the lysis buffer did not affect the NRs, as 
the silica layer is still present.  
Potential mechanisms for the silica degradation could potentially be the acidic pH 
within the endosomal compartment. However, studies in which silica NRs were 
incubated in various acidic solutions suggested this was not the case. On the other hand, 
it is possible that serum proteins are penetrating the porous silica layer and displacing the 
silica layer.
47
 One study found that degradation of silica nanoparticles took place in the 
cytoplasm and lysosomes of HUVECs, followed by exocytosis of the excess silica into 
the cell culture media.
50
 The authors were unsure as to the mechanisms responsible for 
the degradation, but attribute the intracellular environment (including pH and hydrolytic 
enzymes) as the main factor.
50
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The degradation of the silica layer could have important implications. For 
example, photoacoustic imaging can be affected, as the silica provides thermal stability to 
the nanorods
40
 and also causes an enhancement in the photoacoustic signal produced by 
the nanorods
51
. In addition, the degradation of the silica layer could be taken advantage of 
for multimodal applications related to drug/gene delivery, where the molecule to be 
released could be loaded into the silica layer and the NR could provide imaging contrast 
for monitoring purposes.  
4.3.4 Cell viability and function following nanoparticle labeling 
LIVE/DEAD staining and an MTS proliferation assay were used to assess cell 
viability following nanoparticle labeling. Nanoparticle cytotoxicity is dependent upon the 
size, shape, and surface coating of the nanoparticles. In particular, CTAB, a surfactant 
used during nanorod synthesis and which forms a bilayer on the surface of the nanorod, is 
especially cytotoxic to cells, and thus removing or displacing CTAB is necessary to 
reduce the cytotoxic effects.
31,52,53
 Following labeling of MSCs with silica coated NRs, 
MSCs were viable up to 5 days and continued to proliferate, with no significant reduction 
in cell proliferation compared to the control cells (Figure 4.9A, B). Labeling of 
macrophages with 50 nm PEGylated gold nanospheres did not affect cell proliferation or 
viability (Figure 4.9C, D) compared to controls. 
The maintenance of MSC tubular network formation within 3D PEGylated fibrin 
gels was assessed following nanorod labeling and laser irradiation. This was performed to 
verify the process of photoacoustic imaging did not affect the cells’ ability to form 
tubular networks. MSCs without NR labeling or laser irradiation formed extensive 
tubular networks within the gels, and this network formation was maintained following 
NR labeling (Figure 4.10A, B). The gels were also irradiated with an 800 nm laser to 
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ensure photoacoustic imaging did not affect cell function. Both non-labeled cells and NR 
labeled cells continued to form networks following laser irradiation (Figure 4.10C, D). 
These results demonstrate that the cells maintain their function of forming tubular 
networks following NR labeling and photoacoustic imaging. 
4.3.5 In vitro photoacoustic imaging of nanoparticle labeled cells 
In vitro photoacoustic imaging of nanosphere labeled macrophages and NR 
labeled MSCs was performed to evaluate the feasibility of distinguishing and quantifying 
the two cell types using photoacoustic imaging. The two cell types were mixed in various 
ratios and Figure 4.11A shows the spectroscopic results in which the 100% macrophage 
inclusion was identified as having 50 nm PEGylated nanospheres (red) and the 100% 
MSC inclusion was identified as having NRs (green). A transition from nanospheres to 
NRs is evident as the concentration of macrophages decreases and of MSCs increases. 
These results demonstrate that the two cell types can be distinguished based on labeling 
with different nanoparticles, even when they are in close proximity. In addition, the ratios 
of the two cell types were calculated based on the photoacoustic imaging results (Figure 
4.11B), with the predicted cell ratios being a very good estimate of the actual cell ratios 
in the inclusions. Thus, photoacoustic imaging can be used in combination with the dual 
nanoparticle system presented here to quantify the ratios of cells within a region. This 
data would be important for in vivo applications to quantify the infiltration of 
macrophages and the persistence of MSCs following delivery. 
4.3.6 In vivo photoacoustic imaging of nanoparticle labeled cells 
The dual nanoparticle system (consisting of NR labeled MSCs and nanospheres) 
was intramuscularly injected within PEGylated fibrin gel into the gastrocnemius of a rat 
following an ischemic injury. Combined ultrasound and photoacoustic imaging (US/PA) 
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obtained at 800 nm shows a high photoacoustic signal located within the gastrocnemius 
muscle (Figure 4.12A), which persisted until day 7. Spectroscopic analysis attributes the 
photoacoustic signal to NRs (shown in green) immediately after the injection on day 0. 
Over time, the contribution from 50 nm PEGylated nanospheres increases (shown in red), 
and there is a 20% relative increase in signal attributed to the nanospheres from day 0 to 
day 7 (Figure 4.12C). The ratio of the two nanoparticle types was quantified, as shown in 
Figure 4.12B. This increase in signal from nanospheres can be attributed to infiltration of 
macrophages following the ischemic injury and subsequent endocytosis of the PEGylated 
nanospheres by the cells. The endocytosis of the nanospheres by macrophages leads to 
plasmon coupling of the particles,
46
 as demonstrated by the peak shift in Figure 4.1, and 
thus an increase in photoacoustic signal within the range of wavelengths which were used 
for imaging (680-970 nm). A majority of the infiltrating macrophages are localized 
around the delivered hydrogel system containing MSCs. This could be attributed in part 
to the fact that the nanospheres were delivered within the gel system containing the 
MSCs, and thus the nanoparticles which were available for phagocytosis by the 
macrophages were already localized in close proximity to the stem cells. In addition, 
others have shown that macrophages have important roles in wound healing and 
angiogenesis,
24,54,55
 with stem cells and macrophages potentially undergoing some sort of 
synergistic crosstalk to further promote the regeneration process. MSCs have been shown 
to secrete not only angiogenic factors, but also factors which influence macrophage 
function.
27,56,57
 Furthermore, others have found that macrophages are frequently 
associated with endothelial cells during the process of angiogenesis.
58
 In addition, 
chemotactic signals secreted from apoptotic stem cells could also promote macrophage 
migration to the area. Stem cell death following delivery for therapeutic purposes is a 
common issue,
59,60
 and thus it would not be surprising if macrophages are entering the 
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area to scavenge apoptotic MSCs. Thus, one of the advantages of this dual nanoparticle 
system is the ability to distinguish the two cell types in vivo, providing information about 
the interaction between stem cells and macrophage. Such information could include if 
macrophages are phagocytosing MSCs, leading to a transfer of contrast agent from MSCs 
to macrophages. Based on our imaging system, we would designate transfer of contrast 
agent from MSCs to macrophages if there is co-localization of the nanosphere and 
nanorod signal. 
Histological analysis of the muscle sample following sacrifice at day 7 shows the 
presence of injected MSCs (fluorescently pre-labeled with CM-DiI) distributed 
throughout the muscle fibers (Figure 4.13A). In addition, the presence of nanoparticles 
within the cells is evident under bright field. TUNEL staining was performed to assess 
cell apoptosis following injection. The TUNEL staining in Figure 4.13B shows a large 
extent of cell death within the injection region corresponding to the delivered MSCs. It 
has been largely reported in the literature that only a small proportion of stem cells 
survive following delivery.
57,61,62
 Immunostaining for macrophages (ED1) in Figure 
4.13C shows macrophage infiltration within the muscle and in particularly close 
proximity to the injected MSCs, which were fluorescently labeled with CM-DiI prior to 
delivery. The ED1 immunostaining data supports the in vivo photoacoustic imaging 
results, which shows the presence of macrophages on day 7 surrounding the injected 
MSCs. 
4.3.7 Fluorescence-activated cell sorting of macrophages 
Macrophages were sorted from gastrocnemius muscle 7 days following injection. 
ICP-MS analysis confirmed that macrophages endocytosed gold nanoparticles within the 
muscle (Figure 4.14). To confirm that macrophages were not just endocytosing MSCs 
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labeled with gold NRs, a condition consisting of unlabeled MSCs was used. In this 
condition gold was also detected within isolated macrophages, confirming that 
macrophages are endocytosing the gold nanospheres. 
4.4 CONCLUSIONS 
This study demonstrated the use of a dual nanoparticle system to monitor stem 
cells following delivery and to detect the presence of infiltrating macrophages to a wound 
area. Cellular uptake of the nanoparticles was qualitatively and quantitatively assessed in 
vitro using microscopy and mass spectrometry, respectively. In addition, the viability and 
function of the cells was maintained following nanoparticle labeling. An in vitro phantom 
imaging experiment verified that the two cell types could be distinguished and quantified 
using photoacoustic imaging. The stem cells were also successfully monitored following 
intramuscular injection into a hind limb ischemia model, and the increased infiltration of 
macrophages into the area was quantified over time. Histological analysis of 
macrophages confirmed the photoacoustic imaging results, and mass spectrometry 
analysis confirmed that the macrophages had endocytosed gold nanoparticles, and 
specifically gold nanospheres. These results represent important advancements in 
monitoring stem cells for therapeutic purposes and distinguishing the delivered cells from 
infiltrating immune cells, which also have important roles in the wound healing response. 
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Figure 4.1:  Outline of the dual nanoparticle system for labeling MSCs with gold 
nanorods and macrophages with spherical gold nanospheres. The 
nanoparticles exhibit different optical absorption characteristics following 
endocytosis by cells and can thus be distinguished when imaged within the 
tissue optical window (highlighted wavelength region). 
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Figure 4.2:  Characterization of (A) gold nanorods and (B) nanospheres using 
ultraviolet-light spectroscopy, transmission electron microscopy, and zeta 
potential analysis. 
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Figure 4.3:  Analysis of silica coated gold nanorods using transmission electron 
microscopy and energy dispersive spectrometry (red – silicon; green – 
gold). 
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Figure 4.4:  Assessment of nanoparticle labeling of cells using dark field and bright field 
microscopy. Control MSCs are shown in (A) and (B) and nanorod labeled 
MSCs are shown in (C) and (D). Images are overlaid with DAPI 
fluorescence images. Control macrophages are shown in (E) and (F) and 
nanosphere labeled macrophages are shown in (G) and (H). MSCs incubated 
with 50 nm PEGylated nanospheres are shown in (I) and (J). 
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Figure 4.5: Transmission electron microscope images of 70 nm cell sections 
demonstrating endocytosis of nanorods by MSCs and 
localization within membrane bound compartments. 
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Figure 4.6:  Quantification of (A) nanorod labeling of MSCs and (B) nanosphere 
labeling of macrophages and MSCs using inductively coupled plasma 
mass spectrometry. Abbreviations: macrophage (MPH), mesenchymal 
stem cell (MSC), nanorod (NR), nanosphere (NP). 
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Figure 4.7:  (A) Schematic showing a 3D co-culture system of nanorod labeled MSCs, 
macrophages, and nanospheres within a PEGylated fibrin gel. (B) Bright field 
microscopy demonstrating nanoparticle uptake by macrophages within the gels 
(yellow circles). 
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Figure 4.8:  Evaluation of the stability of the nanorod silica coating following 
cellular endocytosis using TEM and EDS analysis (red – silicon; green – 
gold). 
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Figure 4.9:  LIVE/DEAD staining of (A) control and nanorod labeled MSCs and (C) 
control and 50 nm PEGylated nanosphere labeled macrophages at day 5. 
MTS assay of (B) control and nanorod labeled MSCs and (D) control and 
50 nm PEGylated nanosphere labeled macrophages to assess cell 
proliferation. 
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Figure 4.10: 3D stacks of tubular network formation within PEGylated fibrin gels 
for (A. C) unlabeled and (B, D) NR labeled MSCs with (A, B) no laser 
irradiation or (C, D) laser irradiation. 
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Figure 4.11: (A) Spectroscopic in vitro photoacoustic imaging of nanosphere labeled 
macrophages (red) and nanorod labeled MSCs (green) mixed in various 
ratios. (B) Quantification of the ratio of the two cell types based on the 
photoacoustic imaging results. 
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Figure 4.12:  (A) Longitudinal ultrasound/photoacoustic imaging (800 nm) and 
spectroscopic photoacoustic imaging of NR labeled MSCs and nanospheres 
injected within PEGylated fibrin gel into the gastrocnemius. (B) Calculated 
ratio of nanospheres and nanorods. (C) Quantification of the relative 
photoacoustic signal increase attributed to nanospheres compared to day 0. 
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Figure 4.13: (A) Fluorescent microscopy of muscle sections demonstrates the 
distribution of CM-DiI labeled MSCs throughout the muscle fibers. 
Bright field microscopy shows the localization of nanoparticles within the 
cells. (B) TUNEL staining demonstrates MSC death following injection. 
(C) Immunostaining for ED1 cell surface marker demonstrates 
macrophage infiltration. Scale bars = 50 µm. 
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Figure 4.14: Inductively coupled plasma mass spectrometry analysis to 
quantify nanoparticle labeling of macrophages isolated from 
gastrocnemius. Test conditions included nanorod labeled and 
unlabeled MSCs delivered in combination with nanospheres. 
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Chapter 5: In vitro hypoxic modulation of mesenchymal stem cells and 
the resulting effects on macrophage function for ischemic tissue repair 
5.1 INTRODUCTION 
Mesenchymal stem cells (MSCs) possess regenerative properties
1-7
 and have the 
potential to differentiate into various cell and tissue types
6
. It has been suggested that 
these pro-regenerative properties can be enhanced when MSCs are exposed to a hypoxic 
environment.
8-12
 MSCs naturally reside in a hypoxic environment (2-6%) within the bone 
marrow cavity.
8,13-15
 However, following an ischemic injury, where the oxygen level 
drops below 2%, MSCs have been shown to produce improved angiogenic responses.
8-12
 
In comparison to other cell types, MSCs can withstand a severely hypoxic environment 
(less than 2% O2) for at least 48 hours, as they are able to derive the bulk of their ATP 
from glycolysis.
13
 In addition to upregulated expression of pro-angiogenic and pro-
survival factors under hypoxia,
9-11,16,17
 MSCs also secrete factors which influence other 
cell types, including endothelial cells and macrophages,
18,19
 potentially leading to 
improved tissue regeneration
20-22
. 
Many different cell types participate in the wound healing response (including 
fibroblasts, macrophages, and endothelial cells), and the dynamic interplay and 
synergistic effects of these cell types is essential in order for effective wound healing to 
occur. Macrophages are known to have key roles in wound healing processes and to 
participate in angiogenesis and skeletal muscle repair. The role of macrophages include: 
clearing damaged tissue; releasing cytokines to promote wound healing through 
recruitment, proliferation, and differentiation of other cell types; and altering the 
extracellular matrix to produce a more conducive environment for proper tissue 
regeneration.
23,24
 In addition, dynamic changes in macrophage populations (from pro-
inflammatory to regenerative) are essential for efficient wound healing.
25
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Macrophages support wound healing by enhancing angiogenesis. Specifically, 
macrophages secrete proteases (e.g. matrix metalloproteinases (MMPs)) which degrade 
and alter the extracellular matrix and also growth factors and monokines (e.g. 
transforming growth factor (TGF)-α and -β, granulocyte macrophage colony-stimulating 
factor (GM-CSF), vascular endothelial growth factor (VEGF), interleukin (IL)-1 and -6, 
and tumor necrosis factor (TNF)-α) which influence endothelial cell migration and 
proliferation.
24,26
 
Macrophages also have important roles in the regeneration of skeletal muscle 
following an injury. Monocytes are recruited to the injured muscle within 24 hours 
following an injury
20,27,28
 and total impairment of recruitment of monocytes to damaged 
skeletal muscle during this time period prevents muscle repair
20,22,28
. The monocytes 
become activated to macrophages and, as a result of cytokines expressed during Th1-
driven inflammatory responses, such as interferon-γ (IFN-γ) and TNF-α,21,27 are polarized 
to an M1, or pro-inflammatory, phenotype. M1 macrophages secrete pro-inflammatory 
cytokines such as TNF-α and IL-1β, clear damaged tissue by phagocytosing necrotic 
debris, and release cytokines that stimulate myoblast proliferation.
20,27
 Approximately 1-3 
days following M1 activation, the macrophages switch their phenotype to an M2 
phenotype,
20,27,28
 which is known to have a more “regenerative” role compared to M1 
pro-inflammatory macrophages
29
. Conversion into an anti-inflammatory macrophage 
population is necessary for complete wound repair, as anti-inflammatory macrophages 
promote myoblast differentiation and fusion in skeletal muscle.
20-22,27
 M2 macrophages 
are activated by Th2 cytokines such as interleukin (IL)-4, IL-10, and IL-13.
21,27
 M2 
macrophages secrete anti-inflammatory cytokines, including TGF-β and IL-10. M2 
macrophages are often divided into subclasses, which consist of M2a, M2b, and M2c 
phenotypes.
30-33
 Macrophages are stimulated to an M2a phenotype by IL-4 and IL-13 and 
 118 
are thought to promote wound-healing
31
 and participate in the later stages of 
angiogenesis, with high production of PDGF-BB
30
. M2b macrophages are stimulated by 
LPS and IL-1β and are thought to have an immunoregulatory role.23,31 M2c macrophages 
are stimulated by TGF-β and IL-10 and have been shown to participate in matrix 
deposition and tissue remodeling, with high levels of MMP secretion.
23,30
 
Taking into account the role of hypoxia and macrophage function in wound 
healing, this study evaluates the effect of an in vitro hypoxic environment on MSC 
function and phenotype and the resulting interaction with macrophages. It has been 
demonstrated that MSC therapy significantly affects macrophage subpopulations and 
wound repair.
34
 However, the effect of environmental cues on the interaction between the 
two cell types is not well understood, specifically within a wound healing environment. 
Many have implemented hypoxic pre-conditioning methods in order to improve stem cell 
survival and enhance the wound healing response of MSCs following delivery within an 
ischemic site.
10
 While hypoxic pre-conditioned stem cells have shown improvements in 
heart functional recovery
10
 and skeletal muscle and liver regeneration,
9,35
 the resulting 
immunomodulatory effects of stem cells is not well understood. The results of this study 
would provide insights about the mechanisms taking place during the wound healing 
response when utilizing stem cell therapy and the potential benefits of a hypoxic 
environment on stem cell function. 
5.2 MATERIALS AND METHODS 
5.2.1 Human mesenchymal stem cell culture 
Bone marrow-derived human mesenchymal stem cells (hMSCs) (Lonza, 
Walkersville, MD) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 1% 
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glutamax, and 1% penicillin-streptomycin. The cell culture media was changed every 2-3 
days. Cells were passaged using 0.25% trypsin/EDTA (Lonza), collected by 
centrifugation at 600 x g for 7 minutes, and counted with trypan blue exclusion. For all 
experiments, cells were seeded at a density of 5,000 cells/cm
2
. Cells were grown under 
standard cell culture conditions (37°C, 5% CO2). Passage 5-8 hMSCs were used in this 
study. 
Human pre-macrophage-like (monocyte) cell line, U-937 cells (CRL-1593.2™) 
(ATCC), were cultured in suspension in RPMI-1650 growth media supplemented with 
10% FBS and 1% penicillin-streptomycin. For macrophage differentiation, 100 nM of 
12-O-Tetradecanoylphorbol-13-Acetate (TPA) (Cell Signaling Technology) was added to 
the growth media and the cells were cultured for 48 hours.  
5.2.2 Cell culture under hypoxic and normoxic conditions 
Human MSCs were plated at a concentration of 20,000 cells/cm
2
 in growth media 
(10% FBS) and allowed to adhere overnight under normal cell culture conditions (20% 
O2, 5% CO2). Following overnight incubation, the media was replaced with serum free 
cell culture media following washing with phosphate buffered saline (PBS) without 
calcium and magnesium. The cells were placed in either a normoxic (20% O2) or a 
hypoxic (1% or 2% O2) environment for 48 hours. The media was collected every 24 
hours and replaced with serum free media. The media was stored at -80ºC until further 
analysis. In addition, stem cells were also cultured in 2% O2 for 72 hours and the media 
was collected for the macrophage proliferation study.  
For the co-culture experiments, stem cells were seeded in 6 well transwell inserts 
(8 µm pore size) at a concentration of 20,000 cells/cm
2
 in DMEM containing 10% FBS 
and cultured under standard cell culture conditions overnight to allow for adherence. U-
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937 cells which were TPA treated for 48 hours were seeded in 6 well plates at a 
concentration of 400,000 cells/well in RPMI media containing 10% FBS and cultured 
under standard cell culture conditions overnight to allow for adherence. Following 
overnight culture, the media was removed from both cell types and replaced with serum 
free DMEM (1 mL) or 10% FBS (3 mL) containing RPMI media for stem cells and 
macrophages, respectively. The transwell inserts containing stem cells were transferred to 
the 6 well plates containing the macrophages.  The co-cultured cells were then incubated 
under normoxic or 1% hypoxic conditions for 48 hours, after which the media was 
collected and RNA was isolated. In addition, cell proliferation was quantified for both 
cell types using a CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) 
(Promega) as described in section 5.2.3. Macrophage only conditions were also used as 
controls. 
5.2.3 Cell proliferation 
The effect of hypoxic culture on stem cell proliferation was assessed following 
culture in serum free media for 48 hours. Cells were collected by trypsinization and 
diluted 1:10 with serum free media. CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay (MTS) (Promega) was used to measure the cell metabolic activity. 
MTS solution (20% v/v, 200 µl) was added to the cell suspension (1 mL) and allowed to 
incubate for 4 hours under standard cell culture conditions (5% CO2 at 37ºC). After 4 
hours, the cell media was collected and the absorbance levels at 490 nm were measured 
using a microplate reader (BioTek). The metabolic activity of macrophages cultured with 
MSC conditioned media (2% hypoxia for 72 hours) for 24 hours was similarly measured. 
In addition, the metabolic activity of MSCs and macrophages co-cultured under 1% 
hypoxia for 48 hours was also measured. For the co-culture proliferation studies, MSCs 
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and macrophages were co-cultured using 12 well inserts (8 µm pore size). Macrophages 
were not TPA treated prior to culture. 
5.2.4 HIF-1α protein analysis 
A DuoSet ELISA (R&D Systems) was used to detect HIF-1α expression 
following 6 hour incubation of stem cells under 2% hypoxia. Cell protein was collected 
by lysing cells with RIPA buffer (Santa Cruz Biotechnology) supplemented with PMSF, 
protease inhibitor cocktail, and sodium orthovanadate. The cells were incubated with 
lysis buffer for 30 minutes and homogenized by passing the samples through a 21G 
needle ten times at 4ºC. The cell lysates were then centrifuged at 14,000 x g for 20 
minutes (at 4ºC) and the supernatant collected. The samples were then concentrated using 
a 10kD centrifugal filter (Millipore) by centrifuging at 10,000 x g for 5 minutes and the 
samples were retrieved by inverting the centrifugal column in a microcentrifuge tube and 
centrifuging at 1,000 x g for 2 minutes. 
The ELISA plate was prepared and the samples were processed according to the 
manufacturer’s directions. Briefly, the samples were added to the ELISA plate and 
allowed to incubate for 2 hours at room temperature. The plate was then washed with 
washing buffer. The detection antibody was added to the plate and incubated for 2 hours 
at room temperature. Following washing with the washing buffer, Streptavidin-HRP was 
added and incubated for 20 minutes. The plate was washed again and the substrate 
solution was added and incubated for 20 minutes. Finally, the stop solution was added to 
each well and the optical density was measured at 540 nm and subtracted from readings 
at 450 nm to calculate the concentration of protein. 
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5.2.5 Gene analysis 
RNA was isolated from cells using an RNeasy Mini Kit (Qiagen) and 
QIAshredder (Qiagen) according to the manufacturer’s directions. Reverse transcription 
was performed to convert the RNA to cDNA by combining 500 ng of RNA with reagents 
in the High-Capacity cNDA Reverse Transcription Kit (Life Tech) (10x RT buffer, 25x 
dNTP mix, 10x RT random primers, MultiScribe
TM
 Reverse Transcriptase, and nuclease-
free water) according to the manufacturer’s directions.  The cDNA was diluted by 
combining with nuclease-free water in a 1:1 volume ratio. PCR samples were prepared by 
combining cDNA with 2X TaqMan® Fast Universal PCR Master Mix-no AmpErase® 
UNG (Life Tech), specific gene expression assays (Life Tech), and DNase-free water. 
Real-time PCR was performed using a ViiA
TM
 7 machine (Life Tech) with a 
polymerization cycle of 43. Relative gene expression was calculated using a delta-delta-
Ct method by normalizing with gene levels of beta-actin or GAPDH and further 
normalizing with normoxic conditions. For stem cell gene analysis, RNA was collected 
from MSCs cultured under hypoxia (1% or 2%) or co-cultured with macrophages for 48 
hours. For macrophage gene analysis, RNA was collected from TPA treated U-937 cells 
cultured with MSC conditioned media or co-cultured with MSCs. Positive control 
conditions consisted of treating macrophages with the following cytokines: M1 – LPS 
(100 ng/ml) and IFN-γ (20 ng/ml); M2a – IL-4 (20 ng/ml) and IL-13 (20 ng/ml); M2c – 
IL-10 (50 ng/ml). 
5.2.6 Protein analysis 
Protein was collected by lysing cells with RIPA buffer (Santa Cruz 
Biotechnology) supplemented with PMSF, protease inhibitor cocktail, and sodium 
orthovanadate. The cells were incubated with lysis buffer for 30 minutes and 
homogenized by passing the samples through a 21G needle ten times at 4ºC. The cell 
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lysates were then centrifuged at 14,000 x g for 20 minutes (at 4ºC) and the supernatant 
collected. The samples were then concentrated using a 10kD centrifugal filter (Millipore) 
by centrifuging at 10,000 x g for 5 minutes and the samples were retrieved by inverting 
the centrifugal column in a microcentrifuge tube and centrifuging at 1,000 x g for 2 
minutes. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed on a 10% Mini-PROTEAN® TGX
TM
 Precast gel (Bio-Rad Laboratories) at 
room temperature for 1 h at 100 V using a Mini-Protein cell system (Bio-Rad, Hercules, 
CA). The total protein content was quantified using a BCA assay and each sample was 
boiled with an equal volume of 2x Laemmli sample buffer at a ratio of 1:1. Equal 
amounts of total protein (25 µg) were loaded into each well of the gel. Following SDS-
PAGE, proteins were transferred to a PVDF membrane (1 hr at 100 V) and blocked with 
5% milk in 0.1% Tween-20 in TBS (TBST) for 1 h. Membranes were incubated in 
primary antibodies in 5% milk solution at 4ºC overnight (HSP70 1:1000, beta actin 
1:1000), followed by incubation with the secondary antibody in 5% milk solution at room 
temperature for 1 h (goat anti-mouse 1:2000, goat anti-rabbit 1:2000). Chemiluminescent 
substrate (SuperSignal West Dura Extended Substrate, Pierce) was used to visualize 
immunoblotted protein bands. The membranes were imaged using FluorChem Q 
(ProteinSimple) and signal quantification was analyzed using AlphaView software. 
5.2.7 Macrophage migration 
U-937 monocyte cells were fluorescently pre-labeled by collecting the cells, 
washing with PBS, and incubating with calcein AM (4 µM in PBS) at 37ºC for 30 
minutes. The cells were then washed with PBS and resuspended in serum free RPMI 
media. The cells (100,000 cells in 75 µL for the 2% conditioned media and 60,000 cells 
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in 75 µL for the 1% conditioned media) were placed in the top well of a 96 transwell 
insert (8 µm pore size) (Corning Life Sciences) and the conditioned media (50 µL of 
concentrated conditioned media + 200 µL of serum free RPMI media) was placed in the 
bottom of the transwell plate. To quantify cell migration, the fluorescence intensity was 
measured (excitation: 485 nm; emission: 520 nm) at designated time points using a 
BioTek plate reader, and the cell number was calculated using a standard curve. 
5.2.8 Soluble factor secretion 
Enzyme-linked immunosorbent analysis (ELISA) was used to analyze VEGF 
secretion of MSCs under normoxic and hypoxic conditions. Media was collected from 
MSCs cultured under 1% hypoxia or from co-culture of macrophages and MSCs cultured 
under 1% hypoxia. A Quantikine ELISA Kit (R&D Systems) against human VEGF was 
used according to the manufacturer’s instructions. Briefly, the samples were added to the 
ELISA plate (diluted 1:40 in assay diluent) and incubated for 2 hours at room 
temperature. The samples were aspirated and the plate was washed with washing buffer. 
VEGF Conjugate was added to each well and incubated for 2 hours. The plate was 
washed and the substrate solution was added and incubated for 20 minutes. Finally, the 
stop solution was added to each well and the optical density was measured at 450 nm, 
using a wavelength correction at 540 nm. Protein concentrations were normalized to the 
cell number, as determined using an MTS assay. 
Cell culture media was analyzed using a RayBio® Custom C-Series Human 
Array as a broad-spectrum screen for secreted factors. The factors which were analyzed 
included: bFGF, IFN-γ, IGF-1, IL-1α, IL-1β, IL1-Ra, IL-4, IL-6, IL-8, IL-10, IL-13, 
MCP-1, MMP-1, MMP-2, MMP-9, PDGF-1, SDF-1, and TGF-β. Triplicate samples were 
combined for analysis. The membranes were incubated with the media samples overnight 
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at 4ºC, followed by addition of biotinylated antibody and HRP-conjugated streptavidin 
reagents for 2 hours each at 4ºC. The chemiluminscent signal was imaged using 
FluorChem Q (ProteinSimple) and signal quantification was analyzed using AlphaView 
software. A heatmap was generated using the JMP software. 
5.2.9 Statistical analysis 
All test groups consisted of a sample number of 3. Statistical analysis was 
performed using student t-tests with a p value of 0.05. 
5.3 RESULTS AND DISCUSSION 
5.3.1 MSC function under 2% hypoxia 
In order to evaluate the effect of a hypoxic environment on stem cell function, 
bone marrow-derived mesenchymal stem cells were cultured under 2% hypoxia. The 
expression of HIF-1α protein was assessed after 6 hour hypoxic culture (Figure 5.1A). 
HIF-1α is known to be upregulated in response to hypoxia and the downstream effects of 
the HIF-1α pathway include pro-angiogenic and pro-survival mechanisms.11 Also, the 
degree of stabilization of HIF-1α has been shown to be inversely proportional to the 
oxygen concentration.
36
 There was a significant upregulation of HIF-1α protein under 
hypoxic conditions compared to normoxic conditions. In addition, the expression of heat 
shock protein (HSP) 70 was upregulated in MSCs, although not significantly, following 
48 hour hypoxic culture (Figure 5.1B). Stem cell proliferation was significantly increased 
under hypoxia, with MSCs showing a 1.8 fold increase (Figure 5.2A). Others have found 
that MSCs cultured under hypoxia (ranging from 1-5% oxygen) displayed an early start 
of the exponential growth phase and decreased population doubling time, resulting in 
faster proliferation.
13,15,37-39
 MSCs cultured under hypoxia were also found to exhibit a 
larger shortening of telomere length, which was related with the high proliferation rate.
15
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On the other hand, some studies found that hypoxia did not cause faster proliferation of 
MSCs, but instead extended the duration of their proliferation.
8,13,40
 In addition to 
enhanced cell proliferation, hypoxic culture has been found to increase the differentiation 
efficiency of MSCs.
13,15,40
 
Gene analysis was performed to evaluate phenotypic changes in MSCs following 
2% hypoxic culture. As shown in Figure 5.2B, MSCs showed a significant 
downregulation in SMA and upregulation in PECAM compared to normoxic culture. 
MSCs also exhibited an upregulation in MMP2 and VEGF under hypoxia, although not 
significantly. MSCs are known to express pericyte markers such as SMA,
41,42
 and it is 
evident that MSCs undergo a phenotypic change under hypoxia, with upregulation of 
endothelial cell markers. Gene analysis data suggests the cells are transitioning from a 
pericyte-like phenotype to an endothelial-like phenotype, with upregulation of PECAM 
(endothelial marker), VEGF (promotes angiogenesis), and MMP2 (facilitates matrix 
degradation). However, additional morphological and protein analysis is necessary to 
confirm the transition of hypoxic cultured MSCs towards an endothelial phenotype. 
5.3.2 Influence of MSC conditioned media (2% hypoxia) on macrophages 
U-937 monocytes were cultured with conditioned media collected from stem cells 
cultured under normoxia and 2% hypoxia. Following 48 hour incubation with 
conditioned media, U-937 proliferation was evaluated. Monocytes cultured with MSC 
normoxic and hypoxic conditioned media had substantially enhanced cell proliferation 
compared to the serum free condition (Figure 5.3A), although there was no difference 
between the MSC hypoxia and normoxia conditioned media. Thus, under normoxic 
culture conditions MSCs secrete factors which are mitogenic for monocytes, but this 
effect is not significantly enhanced within hypoxic environments. 
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The chemoattractive effects of MSC conditioned media on macrophages was 
evaluated using a modified Boyden’s assay (Figure 5.3B). Conditioned media from 
MSCs cultured under 2% hypoxia did not exhibit significant chemoattractive effects 
compared to normoxic conditions. Others have seen chemoattractive effects of MSCs 
cultured under hypoxia, with enhanced monocyte migration after 2 hours compared to 
control media.
18
 However, differences in culture conditions and experimental design 
could potentially be the cause for these differences between this study and studies by 
others. Specifically, Chen et al
18
 cultured MSCs under a much more severe hypoxic 
environment (0.5% O2 for 24 hours) compared to our study and saw some differences in 
macrophage migration. Thus, it is possible that MSCs secrete more chemoattractive 
factors for macrophages under more severe hypoxic conditions. 
Evaluation of macrophage phenotype along the M1/M2 spectrum was performed 
using gene analysis. Positive control conditions consisted of treating macrophages with 
certain cytokines to induce changes towards a specific macrophage phenotype (M0, M1, 
M2a, or M2c). The markers chosen for the M1 and M2 subclasses were selected based on 
the literature.
23,30,43
 The data (Figure 5.4) shows that CCR7 identified M1 macrophages, 
arginase-1 (Arg1) identified M2 (specifically M2a) macrophages, and CD163 identified 
M2c macrophages. CD206 is identified as an M2a phenotypic marker.
30
 However, gene 
analysis did not show a substantial upregulation of CD206 for M2a macrophages. This 
could potentially be attributed to the fact that the concentrations of cytokines used to 
induce differentiation were not high enough, or the time point of analysis (24 hours) was 
not optimal. Analysis of macrophages incubated with normoxic or hypoxic conditioned 
media showed there were not substantial changes in macrophage phenotype. While trends 
showed an upregulation in M2c, this change was not significant. As a result, it was 
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concluded that conditioned media collected from MSCs cultured under 2% hypoxia did 
not significantly influence macrophage phenotype.  
5.3.3 MSC function under 1% hypoxia 
Typically within the wound environment cells encounter hypoxic conditions less 
than 2% O2. Thus, the effect of a more severe hypoxic environment (1% O2) on stem cell 
function was evaluated. Under more severe hypoxic culture, stem cells showed a 
dramatic upregulation in cell proliferation, with a 3.16 fold increase compared to 
normoxic culture (Figure 5.5A). Gene analysis was performed to evaluate phenotypic 
changes in MSCs following 1% hypoxic culture (Figure 5.5B). MSCs showed a 
significant downregulation in SMA and an even more dramatic upregulation of VEGF 
compared to 2% hypoxia. MSCs also exhibited an upregulation in MMP2 and 
downregulation in PECAM under 1% hypoxia, although not significantly. Similar to the 
2% hypoxic conditions, this data suggest a transition from a pericyte phenotype to an 
angiogenic promoting phenotype. 
5.3.4 Influence of MSC conditioned media (1% hypoxia) on macrophages 
Migration of U-937 monocytes with conditioned media from MSCs cultured 
under 1% hypoxia was evaluated using the same method as for the 2% hypoxia media. 
Based on the 2% hypoxia migration study, we hypothesized that the optimal chemotactic 
effect would be during the earlier time points following incubation with the conditioned 
media. As a result, more early time points were evaluated for the 1% hypoxia case. 
However, conditioned media from MSCs cultured under 1% hypoxia did not exhibit 
significant chemoattractive effects compared to normoxic conditions (Figure 5.6). It is 
possible that MSCs are secreting factors which are chemoattractive for macrophages, but 
they are in such low concentration and thus do not significantly influence macrophage 
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migration. It is also possible that MSCs might have more significant chemotactic effects 
on macrophages under a more severe hypoxic environment (<1% O2).
18
 
Macrophage phentoyope was evaluated using gene analysis (Figure 5.7).  Similar 
to the 2% conditioned media, the 1% conditioned media also did not elicit substantial 
phenotypic changes in macrophages. It is possible that the MSCs were not secreting high 
enough concentrations of cytokines to elicit a response from macrophages. In addition, 
the co-culture of macrophages and MSCs may be necessary in order to produce 
synergistic effects and allow for cross-talk between the two cell types and enhanced 
paracrine and autocrine effects.
19,44,45
  
5.3.5 MSC soluble factor secretion under severe (1%) hypoxia 
Analysis of the soluble factors secreted by MSCs under 1% hypoxia was 
performed using a cytokine array (Figure 5.8). Of the 18 factors analyzed, only 5 were 
detectable (IL-6, MCP-1, bFGF, MMP-1, and IL-8). Under hypoxia MSCs secreted 
higher levels of IL-6. Although IL-6 is traditionally considered to be a pro-inflammatory 
cytokine, it is necessary for complete wound healing to occur,
19,46
 as demonstrated by the 
lack of wound healing in IL-6 deficient mouse,
46
 and is also considered pro-angiogenic.  
MMP-1 and bFGF are also factors which are important for angiogenesis, but there were 
minimal differences in secretion levels of these factors under hypoxia versus normoxia.  
IL-8 and MCP-1 are chemokines which drive the infiltration of neutrophils and 
macrophages to the wound area following an injury.
47
 Although these factors were 
slightly upregulated under hypoxia, the migration results in Figure 5.6 demonstrate they 
were not secreted in a high enough concentration to elicit a response from macrophages. 
The secretion of VEGF was quantified using an ELISA (Figure 5.9). MSCs 
cultured under 1% hypoxia secreted significantly higher amounts of VEGF compared to 
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normoxic conditions. However, when normalizing by the cell number, there was not a 
significant difference between normoxic and hypoxic conditions. This suggests that the 
total amount of VEGF is increased as a result of the increase in cell number, and not 
necessarily due to the increased secretion of VEGF per cell. Other investigators who have 
seen upregulated secretion of VEGF by MSCs under hypoxia only reported total VEGF 
and did not normalize by cell number.
9,48-52
 Some have reported upregulated VEGF 
secretion per cell, but in this case both secreted and intracellular VEGF were quantified,
53
 
which is in contrast to our study in which only secreted VEGF was quantified. However, 
VEGF gene expression analysis of MSCs under 1% hypoxia showed a significant 
upregulation compared to normoxia (Figure 5.5B), which suggests that on the cellular 
level VEGF is upregulated in terms of gene expression, but not for protein, at the 48 hour 
time point. 
5.3.6 Cross-talk between MSCs and macrophages within a hypoxic environment 
Previous studies have demonstrated that stem cells can potentially have an 
influence on macrophage function and phenotype, essentially producing “mesenchymal 
stem cell-educated macrophages”.19,44,45. Kim et al showed that co-culture of stem cells 
and macrophages produced more dramatic results in terms of influencing macrophages.
19
 
As a result, the co-culture of MSCs and macrophages under hypoxic (1% O2) and 
normoxic conditions was evaluated. The co-culture was performed using a transwell 
insert and the cells were separated and analyzed following incubation. Analysis of MSC 
function showed a significant upregulation in cell proliferation (2.8 fold increase) under 
hypoxia compared to normoxia (Figure 5.10A), similar to that seen for the 2% and 1% 
hypoxia experiments in sections 5.3.1 and 5.3.3, respectively. Gene expression analysis 
of MSCs co-cultured with macrophages again showed a downregulation of SMA under 
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hypoxia. In addition, all of the endothelial and angiogenic markers were upregulated 
under hypoxia, including significant upregulation of PECAM and VEGF (Figure 5.10B). 
Macrophages co-cultured with MSCs under hypoxia had significantly higher 
proliferation compared to normoxic co-culture (Figure 5.11). In addition, macrophages 
cultured alone under hypoxia (not with MSCs) had significantly higher proliferation 
compared to normoxic conditions. Interestingly, it appears that MSCs enhance the 
proliferation of macrophages when cultured under hypoxia, as evident when comparing 
macrophages co-cultured with MSCs and macrophages cultured alone under hypoxia. 
Macrophage proliferation is influenced by macrophage colony-stimulating factor, 
granulocyte-macrophage colony-stimulating factor, and IL-3.
54-56
 However, additional 
analysis and quantification of the production of these cytokines under normoxia and 
hypoxia are needed. 
Phenotypic changes of macrophages co-cultured with MSCs were also analyzed 
(Figure 5.12) and compared to macrophages cultured alone. Gene expression analysis 
showed a significant increase in CCR7, an M1 marker, for both co-cultured macrophages 
and macrophages alone under hypoxia. Arg1 expression, an M2 marker, was significantly 
increased for the co-cultured macrophages and significantly decreased for the 
macrophages alone under hypoxia. The other markers (CD206 and CD163) did not show 
significant changes. Taking the ratio of M1/M2 (CCR7/Arg1) showed a significant shift 
towards an M1 phenotype for macrophages cultured alone under hypoxia. On the other 
hand, macrophages co-cultured with MSCs under hypoxia were not stimulated towards 
an M1 phenotype and showed a trend towards an M2 phenotype, although it was not 
significant. Others have seen changes in macrophage function in response to hypoxia. 
Most notably, macrophages cultured under hypoxia showed upregulation of pro-
angiogenic factors, including VEGF.
57,58
 However, the phenotypic changes induced by 
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hypoxia is more differential and is dependent upon the duration and extent of hypoxia, 
the cell type and source, and previous priming of the macrophages (such as with 
LPS).
57,59
 In general, hypoxia is found to lead to the release of inflammatory cytokines, 
including TNF-α, IL-1, IL-6, and iNOS,57,58,60 and some have claimed hypoxia is a 
stimulus for M1 activation
57,60,61
. It has also been suggested that the initial immune 
response to hypoxia is an exaggerated inflammatory stage, with secretion of pro-
inflammatory factors.
57,59
 This acute response is then followed by the release of anti-
inflammatory cytokines.
57
 The shift between these two phases is most likely due to 
external factors, including neighboring cells. Our results support this statement, in that 
macrophages cultured alone show an enhanced M1 response, whereas macrophages co-
cultured with MSCs do not shift towards an M1 phenotype. 
5.3.7 Effect of hypoxia and culture conditions on soluble factor secretion  
Soluble factor secretion of macrophages and MSCs co-cultured under 1% hypoxia 
was analyzed using a cytokine array (Figure 5.13). Of the 18 factors analyzed, only 5 
were detectable (IL-6, MCP-1, IL-10, MMP-1, and IL-8). For the co-culture condition, 
IL-10 and MMP-1 production was increased under hypoxia compared to normoxia, while 
IL-6 production was slightly decreased. IL-10 is an anti-inflammatory cytokine which 
activates macrophages to an M2 phenotype (specifically M2c)
21,27
 and is also secreted by 
M2 macrophages
23,30
. There was a slight increase in MCP-1 secretion under hypoxia and 
a decrease in secretion of IL-8. For the macrophages cultured alone under hypoxia, there 
was an increase in the production of IL-6 and IL-10 and of the pro-angiogenic factor 
MMP-1. There was a decrease in MCP-1 and IL-8 under hypoxia.  
When comparing the differences in soluble factor secretion between the two 
culture conditions under normoxia, it was found that production of IL-6 and IL-10 were 
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increased for the co-culture system (Figure 5.14). It has been shown co-culture of 
macrophages and MSCs leads to enhanced secretion of IL-10 by macrophages and of IL-
6 by both cell types.
19,44,45
 Under hypoxia, it was found that production of IL-6, MCP-1, 
IL-10, MMP-1, and IL-8 were enhanced for the co-culture system. IL-8 and MCP-1 are 
chemotactic factors for macrophages, and thus future studies could include analyzing the 
effect of conditioned media collected from co-cultured MSCs and macrophages on 
macrophage migration. Overall, these results demonstrate that culturing MSCs with 
macrophages under hypoxia leads to enhanced secretion of pro-angiogenic and anti-
inflammatory cytokines.  
Others have demonstrated that MSCs influence macrophages, either through 
direct culture or soluble factor secretion, to express higher levels of CD206, increased 
production of IL-10 and IL-6, and decreased production of IL-12 and TNFα.19,44 These 
trends hold true for the current study, as analysis of the soluble factors secreted from the 
co-culture of MSCs and macrophages showed higher levels of IL-6 and IL-10 compared 
to macrophages alone. However, the cell source (i.e. MSCs or macrophages) of the 
soluble factors is not known in the co-culture system. With that said, MSCs cultured with 
macrophage conditioned media have also been shown to have increased IL-6 
production.
45
  Although IL-6 is essential in the wound healing process
19,46,62
 and is 
usually considered to be pro-inflammatory, it can also play an anti-inflammatory role by 
potentially regulating the levels of pro-inflammatory cytokines such as IL-1 and TNFα63. 
Furthermore, M2b macrophages express high levels of IL-6.
19
 
In addition, the co-culture of MSCs and macrophages resulted in enhanced VEGF 
secretion under 1% hypoxia (Figure 5.15), although it was not significant. Thus, even 
under normoxia, the combination of MSCs and macrophages leads to upregulated 
expression of VEGF which is not further enhanced under hypoxia. This is in contrast to 
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MSCs cultured alone (Figure 5.9), in which there were lower basal levels of VEGF 
expression under normoxia which was significantly upregulated under hypoxia. The 
VEGF secretion can be attributed to both the MSCs and the macrophages and the co-
culture of the two cell types. When comparing the co-culture condition to macrophages 
cultured alone for the 1% hypoxia, there was a significant increase in VEGF secretion for 
the co-culture condition under hypoxia. This could be due to the paracrine and autocrine 
effects of the stem cells and macrophages being cultured together, as both cell types have 
been demonstrated to secrete VEGF.  
5.4 CONCLUSIONS 
This study investigated the effect of a hypoxic environment on MSCs and the 
subsequent effects on the interaction between MSCs and macrophages. Various culture 
conditions were analyzed, including mild (2% O2) and severe (1% O2) hypoxia, as well as 
culture of macrophages with MSCs or MSC conditioned media. MSCs exhibited a stress 
response under hypoxia, with upregulation of pathways (HIF-1α and HSP70) which are 
pro-angiogenic and pro-survival. Quantitative analysis showed increased expression of 
angiogenic and endothelial factors under mild hypoxia, with an enhanced expression 
under severe hypoxia. Culturing macrophages with MSC conditioned media did not result 
in enhanced macrophage proliferation compared to normoxic conditions, although it 
appeared that MSCs are secreting factors even under normoxic conditions which sustain 
macrophage proliferation. However, co-culturing MSCs with macrophages under hypoxia 
did lead to a significant upregulation in macrophage proliferation, demonstrating the need 
for cross-talk between the two cell types. In addition, significant changes in macrophage 
phenotype only occurred when the cells were co-cultured with MSCs, with macrophages 
not shifting towards an M1 phenotype. Analysis of cytokine secretion under the various 
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culture conditions (conditioned media and co-culture) showed that for MSCs cultured 
under severe hypoxia, secretion of IL-6 was substantially upregulated under hypoxia, 
while other chemoattractive (MCP-1 and IL-8) and pro-angiogenic (MMP-1) cytokines 
were slightly upregulated. In addition, total VEGF secretion was significantly higher for 
MSCs cultured under hypoxia compared to normoxia. On the other hand, analysis of the 
co-culture condition compared to macrophages alone showed substantial upregulation in 
pro-angiogenic and anti-inflammatory cytokines under hypoxia, including IL-6, MCP-1, 
IL-10, MMP-1, and IL-8. Although IL-6 is sometimes considered to be pro-
inflammatory, it has important roles in wound healing. Total VEGF secretion was 
significantly higher for the co-cultured cells compared to macrophages only under both 
normoxic and hypoxic conditions. Overall this study provides insights into the response 
of MSCs and macrophages to hypoxia and the essential cross-talk between the two cell 
types. 
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Figure 5.1:  Quantification of (A) HIF-1α and (B) HSP70 protein expression by MSCs in 
response to 2% hypoxia. (* = p<0.05 compared to normoxia) 
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Figure 5.2:  (A) MSC proliferation and (B) gene expression after 48 hour culture 
under normoxic or 2% hypoxic conditions. (* = p<0.05 compared to 
normoxia)  
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Figure 5.3: Effect of 2% hypoxic MSC conditioned media on (A) macrophage 
proliferation and (B) macrophage migration. 
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Figure 5.4: Phenotype analysis of macrophages following 24 hour culture with 2% 
hypoxic MSC conditioned media. Abbreviations: normoxia (N), hypoxia 
(H). 
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Figure 5.5: (A) MSC proliferation and (B) gene expression after 48 hour culture under 
normoxic or 1% hypoxic conditions. (* = p<0.05 compared to normoxia) 
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Figure 5.6:  Effect of 1% hypoxic MSC conditioned media on macrophage migration. 
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Figure 5.7: Phenotype analysis of macrophages following 24 hour culture with 2% 
hypoxic MSC conditioned media. 
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Figure 5.8: Secretion of various factors by MSCs analyzed by human cytokine 
membrane array following 1% hypoxic culture.  
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Figure 5.9: VEGF secretion of MSCs cultured 1% hypoxia. (* = p<0.05 compared to 
normoxia).  
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Figure 5.10: (A) MSC proliferation and (B) gene expression after 48 hour co-culture 
with macrophages under normoxic or 1% hypoxic conditions. (* = p<0.05 
compared to normoxia) 
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Figure 5.11: Macrophage proliferation following 48 hour culture under normoxia or 1% 
hypoxia. Macrophages were either cultured individually or co-cultured 
with MSCs. Macrophages cultured alone with 10% FBS containing media 
(growth media) was used as a positive control. (* = p<0.05) 
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Figure 5.12: Phenotype analysis of macrophages under 1% hypoxia following either 24 
hour co-culture with MSCs or cultured alone. (* = p<0.05 compared to 
normoxia). Abbreviations: normoxia (N), hypoxia (H). 
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Figure 5.13: Effect of hypoxic culture (1% O2) on secretion of various factors by co-
cultured MSCs and macrophages or macrophages cultured alone, analyzed 
by human cytokine membrane array. Data is normalized to normoxic 
condition. 
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Figure 5.14: Effect of culture condition (co-cultured MSCs and macrophages or 
macrophages cultured alone) on secretion of various factors under 
normoxia or 1% hypoxia, analyzed by human cytokine membrane array. 
Data is normalized to macrophage only condition. 
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Figure 5.15: VEGF secretion of co-cultured MSCs and macrophages under 1% hypoxia. 
(* = p<0.05) 
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Chapter 6: Therapeutic contribution of mesenchymal stem cells 
following an ischemic injury 
6.1 INTRODUCTION 
Peripheral artery disease (PAD) is a growing health concern in the United States, 
with 8-10 million people being affected by the disease.
1
 Intermittent claudication is an 
early, moderate manifestation of the disease and is characterized by leg pain and muscle 
weakness.
1,2
 However, PAD can quickly develop into critical limb ischemia, which is a 
more chronic and severe problem.
1,2
 Critical limb ischemia often results in tissue 
infection, death, and potentially amputation because the resting metabolic needs of the 
tissue are not met by the available blood supply.
1,2
 Although current revascularization 
therapies (including bypass surgery and balloon angioplasty) may provide some benefit 
to patients, not all patients are eligible for such procedures.
1-4
 Major limb amputation is 
often necessary if revascularization therapy is not possible, or was not successful.
3,4
  
Many have investigated the use of angiogenic gene and protein therapy as an 
alternative revascularization strategy.
2,5,6
 Although gene and protein strategies have 
shown some success in preclinical animal models, there have not been significant 
improvements in clinical studies.
5,6
 This could potentially be attributed to the fact that the 
ischemic wound healing response is very complex, and thus delivering the correct 
genes/proteins is very difficult,
5,6
 especially when taking into account necessary temporal 
release kinetics and concentration gradients. As a result, cell-based approaches are an 
attractive therapy option because the cells can supply the necessary cytokines and growth 
factors necessary to promote, as well as support, vascular regeneration.
2
 In addition, the 
use of multipotent stem cells, such as bone marrow-derived mesenchymal stem cells 
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(MSCs), could provide the advantage of replacing compromised tissue in addition to 
generating blood vessels.
2
 
This study evaluated the use of bone marrow-derived mesenchymal stem cells as 
a therapy for peripheral arterial disease. A rat model of acute hind limb ischemia was 
used in which the femoral artery was ligated and excised. MSCs were intramuscularly 
delivered within a PEGylated fibrin biomatrix following ischemia. The PEGylated fibrin 
delivery system offers many advantages, including retaining MSCs at the delivery site. In 
addition, fibrin is a natural component of the wound healing response and has been 
demonstrated to have angiogenic properties.
7,8
 To evaluate the therapeutic contribution, 
restoration of blood flow and muscle function were evaluated. Histological analysis was 
also performed to evaluate tissue architecture and blood vessel formation. The results of 
this study have important implications pertaining to alternative cell-based therapies for 
ischemic and cardiovascular diseases.  
6.2. MATERIALS AND METHODS 
6.2.1 Ischemic injury 
Animal handling and care followed the recommendations of the National 
Institutes of Health (NIH) guidelines for the care and use of laboratory animals. All 
protocols were approved by the Animal Care Committee at the University of Texas at 
Austin. Lewis rats (11 weeks) weighing 250-300 g were used. To induce hind limb 
ischemia, femoral artery ligation in Lewis rats (11 weeks, male) was performed. Rats 
were anesthetized using isoflurane (0.5-2%) infused with oxygen (2 L/min). Through a 
small incision on the medial side of the thigh, the femoral artery of a single hind limb was 
separated from the nearby nerve and vein and ligated immediately distal to the inferior 
epigastric artery and proximal to the branch point of the popliteal and saphenous arteries 
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using Prolene 5-0 sutures (Figure 6.1). The ligated segment (~0.5 cm) was then excised 
and the skin incision closed with interrupted sutures. The animal was allowed to recover 
overnight and the following day (about 24 hours later) therapy was delivered.  
6.2.2 Syringe viability study 
Cell viability following injection within PEGylated fibrin gels was evaluated 
using a LIVE/DEAD stain. PEGylated fibrin injections were prepared by combining 
difunctional succinimidyl glutarate PEG (4 mg/mL in PBS without calcium; NOF 
America) with fibrinogen (40 mg/mL in PBS without calcium; Sigma) in a 1:1 volume 
ratio. An equal volume of rat MSCs (passage 5) was mixed with the PEGylated fibrin 
solution in a 1:1 volume ratio at a concentration of 2x10
5
 cells/mL. The solution was then 
loaded into a 23G needle syringe, followed by an equal volume of thrombin (25 U/mL in 
40 mM CaCl2). The solution was mixed thoroughly within the syringe and the gel 
solution (500 µL) was injected into a 24 well plate.  The final concentrations in the gel 
were 5 mg/mL of fibrinogen; 0.5 mg/mL of SG-PEG-SG; 5x10
5
 cells/mL; and 12.5 
U/mL of thrombin. A gel which was formed in the well plate and not injected through a 
syringe was used as a positive control. The gels were stored at 37ºC in MSC growth 
media. Twenty four hours following the injection, the cells were stained with a 
LIVE/DEAD stain to assess cell viability. Briefly, the media was removed and the gels 
were washed with PBS for 15 minutes. The PBS washes were repeated for a total of 90 
minutes. The gels were then incubated in a LIVE/DEAD stain solution consisting of 10 
µM calcein and 10 µM ethidium homodimer for 1 hour at 37ºC. The stain was removed 
and the gels were washed with PBS, fixed in 10% formalin for 20 minutes, washed with 
PBS, and imaged on a Leica DMI2000B microscope equipped with a Leica DFC290 
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camera. Gels incubated with methanol prior to staining were used as a dead control 
condition. 
6.2.3 PEGylated fibrin gel delivery of MSCs 
MSCs were injected intramuscularly into the gastrocnemius muscle of the ligated 
limb. PEGylated fibrin injections were prepared by combining difunctional succinimidyl 
glutarate PEG (4 mg/mL in PBS without calcium; NOF America) with fibrinogen (40 
mg/mL in PBS without calcium; Sigma) in a 1:1 volume ratio. An equal volume of MSCs 
was mixed with the PEGylated fibrin solution in a 1:1 volume ratio at a concentration of 
13x10
6
 cells/mL. The solution was then loaded into a 23G needle syringe, followed by an 
equal volume of thrombin (25 U/mL in 40 mM CaCl2). The solution was mixed 
thoroughly within the syringe and the gel solution (300 µL) was injected into the 
gastrocnemius of the rat.  The final concentrations in the gel were 5 mg/mL of fibrinogen; 
0.5 mg/mL of SG-PEG-SG; 3.33x10
6
 cells/mL; and 12.5 U/mL of thrombin. Other 
treatment groups consisted of no treatment, PEGylated fibrin gel, and MSCs. For the 
PEGylated fibrin gel treatment, 300 µL of PEGylated fibrin gel was injected into the 
lateral gastrocnemius muscle, with the cell portion replaced by 10% FBS containing 
DMEM. For the MSC treatment, 300 µL of MSCs (3.33x10
6
 cells/mL) suspended in 10% 
FBS containing DMEM was injected into the lateral gastrocnemius muscle. Prior to 
delivery, MSCs were fluorescently labeled with CellTracker
TM
 CM-DiI (Invitrogen). The 
cells were incubated with CM-DiI (15 µM) at 37ºC for 8 minutes and then 4ºC for 15 
minutes, washed with PBS, and resuspended in DMEM. 
6.2.4 Blood flow measurements  
Thermal infrared imaging was performed to evaluate blood flow to the ischemic 
hind limbs. Rats were anesthetized using isoflurane (0.5-2%) infused with oxygen (2 
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L/min) and imaged with an FLIR A325sc camera. The rats were put in the prone position, 
with the dorsal side up and the ventral side down. The hind limbs were imaged for a total 
of 3 minutes, acquiring a total of 180 frames. The images were acquired and processed 
using FLIR ExaminIR. The difference between the average temperature of the ischemic 
and control contralateral limb were used for quantification.  
6.2.5 Force production measurements 
Force production measurements of the lateral gastrocnemius muscle were 
conducted on all treatment groups with sample size of 5. The gastrocnemius muscle was 
surgically isolated from the surrounding tissue and innervation to the medial 
gastrocnemius muscle was removed. The Achilles tendon was secured to the lever arm of 
a dual-mode servomotor (Aurora Scientific Model 310B). The muscle was stimulated 
using a stimulator (A-M Systems Model 2100) with electrodes applied to the tibial nerve. 
The optimal length, or the length which produced the maximal twitch force, was 
determined by stimulating the muscle at 0.5 Hz. The maximal peak tetanic tension was 
measured by stimulating the muscle at the optimal length at a frequency of 150 Hz and 
the minimal voltage required to elicit a maximal response. Between each contraction 
there was a 2 minute period of rest. The temperature of the muscle was maintained with a 
heating lamp throughout the duration of the study. At the end of the study, the animal was 
sacrificed and the lateral gastrocnemius muscle was isolated. The muscle mass and 
muscle length were measured in order to calculate the cross sectional area (Equation 1), 
where Q is the fiber angle from the mid-line (19º). The fiber length is calculated by 
multiplying the muscle length by 0.38 (fiber length/muscle length ratio for the 
gastrocnemius), and the density of skeletal muscle is 1.056 g/cm
3
. The specific tension 
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was calculated using Equation 2. The specific tension was normalized to the contralateral 
control (% of contralateral control). 
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6.2.6 Histology 
At the terminal endpoint of the study, animals were sacrificed and the 
gastrocnemius muscles were isolated, embedded in optimal cutting temperature (OCT) 
compound, submerged in liquid nitrogen-cooled isopentane, and stored at -80ºC until 
further processing. The samples were cut into 12 µm thick sections using a cryostat and 
placed onto positively charged microscope slides. The tissue sections were fixed in 10% 
formalin for 15 minutes. Hematoxylin and eosin (H&E) and imunohistochemical staining 
were subsequently performed. 
For H&E staining, the slides were fixed in 10% formalin for 15 minutes, followed 
by rinsing with PBS. The sections were then incubated in Mayer’s hematoxylin solution 
(Electron Microscopy Sciences) for 15 minutes and rinsed in running tap water for 15 
minutes. The sections were then dipped in Scott’s bluing solution for 30 seconds, rinsed 
in distilled water for 30 seconds, and incubated in 95% ethanol for 30 seconds. The 
samples were then transferred into Eosin Y solution (Sigma-Aldrich) for 1 minute 
followed by serial washes in 95% ethanol, 100% ethanol, and xylene for 2 minutes each. 
The slides were then mounted with Cytoseal Mounting Media (Thermo Scientific) and 
viewed with a DMI2000B Leica microscope.  
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For immunohistochemistry, the slides were fixed in 10% formalin for 15 minutes, 
followed by rinsing with PBS. The sections were then incubated in 0.125% trypsin 
solution for 20 minutes at 37ºC. They were then incubated in 0.3% hydrogen peroxide 
solution for 5 minutes, permeabilized in 0.5% Triton X-100 in TBST for 30 minutes, and 
blocked in 2.5% horse serum for 1 hour. The slides were incubated overnight at 4ºC in 
the primary antibody (1:100 dilution in 2.5% horse serum) (SMA; Abcam). Following 
overnight incubation, the sections were incubated with ImmPRESS (rat absorbed mouse 
IgG) solution (Vector Laboratories) for 30 minutes and then ImmPACT DAB peroxidase 
substrate (Vector Laboratories) for 5 minutes. The sections were counterstained with 
hematoxylin QS (Vector Laboratories), rinsed with running tap water, incubated in serial 
concentration of ethanol (95% and 100%) and xylene for 2 minutes each, and mounted. 
The SMA positive area and the number of SMA positive vessels were quantified using 
ImageJ. 
6.2.7 Statistical analysis 
All test groups consisted of a sample number of 5. Statistical analysis was 
performed using student t-tests with a p value of 0.05. 
6.3 RESULTS AND DISCUSSION 
6.3.1 Assessment of MSC viability following syringe injection 
The in vivo delivery of the stem cells via syringe injection was evaluated to 
determine if this delivery method was feasible and did not damage MSCs. It has been 
demonstrated that MSCs can survive and maintain phenotypic and functional 
characteristics following passage through a needle as small as 26G.
9
 In addition, the 
encapsulation of MSCs within a hydrogel system, such as PEGylated fibrin, may serve as 
a protective barrier to minimize cell death as a result of delivery via syringe injection.
10
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Cell viability following injection within PEGylated fibrin gel was evaluated in vitro using 
a LIVE/DEAD stain. Stem cells which were passed through a 23G needle did not 
undergo cell death, as demonstrated by the large extent of viable cells (Figure 6.2). 
Control conditions consisted of cells encapsulated within a PEGylated fibrin gel which 
had not been passed through a syringe, and a dead control for staining purposes.  
6.3.2 Perfusion of ischemic tissue 
Quantification of blood vessel formation in the treatment groups was performed 
using smooth muscle actin (SMA) staining (Figure 6.3). Quantification of the SMA 
positive area showed no differences between treatment groups on day 7, but significantly 
enhanced blood vessel formation for the PEGylated fibrin gel and MSCs + PEGylated 
fibrin gel groups on day 14. Quantification of the total number of SMA positive vessels 
produced similar results, with significantly enhanced blood vessel formation for the 
PEGylated fibrin gel on day 14 and MSCs + PEGylated fibrin gel group on days 7 and 
14. Fibrin has a high affinity for various growth factors and cytokines (including pro-
angiogenic factors such as VEGF,
11
 IGF,
12
 and TGF-β13) and supports angiogenesis and 
tissue repair.
14
 This could account for the enhanced blood vessel formation in the 
PEGylated fibrin gel treatment group. 
Reperfusion of the ischemic hind limb was indirectly evaluated using thermal 
infrared imaging and calculating the temperature difference between the ischemic limb 
and contralateral control. Thermal infrared imaging has been demonstrated to be an 
accurate tool to assess circulatory changes and thus reperfusion of ischemic tissue.
15,16
 On 
day 14 there were significant improvements in reperfusion of the ischemic hind limb for 
the PEGylated fibrin gel and MSCs + PEGylated fibrin gel treatment groups (Figure 6.4).  
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6.3.3 Functional recovery of ischemic tissue 
In order to evaluate the localization and distribution of MSCs following injection, 
the cells were fluorescently labeled prior to delivery. Figure 6.5 shows the distribution of 
the cells for the MSC and MSC + PEGylated fibrin gel groups at day 7 and day 14. The 
cells are distributed throughout the muscle fibers and are present until day 14. However, 
as evidenced in Figure 4.13B, a majority of the cells are most likely no longer viable, 
especially at day 14. 
Tissue necrosis is typically evaluated histologically by the presence of multi-
cellular infiltrates and muscle fibers which are inhomogeneous in size, hypereosinophilic, 
and devoid of nuclei.
17
 Histological analysis of all treatment groups on day 7 and day 14 
showed no evidence of inflammation or necrosis, even for the no treatment group (Figure 
6.6). This lack of tissue damage is likely due to the fact that the rat underused the ligated 
limb following surgery and also that collateral flow was sufficient to provide blood to the 
tissue, especially at later time points.
18-20
 Subjecting the rats to more physical activity 
following surgery has been shown to exacerbate the adverse effects of ischemia because 
of impaired limb blood flow capacity with stress,
21
 with enhanced capillary endothelial 
swelling and white blood cell activation.
18,22
 Along the same lines, reperfusion of 
ischemic tissue results in oxidative stress caused by the generation of reactive oxygen 
species, resulting in extensive tissue damage.
12,23-25
 
Functional recovery of the ischemic tissue was evaluated using force production 
measurements (Figure 6.7). Functional assessments (quantified as the % of contralateral 
control) at day 7 showed a significant improvement in specific tension (p<0.05) for the 
MSC (81.03 ± 6.35%) treatment group compared to no treatment (66.50 ± 3.10%). The 
MSC + PEGylated fibrin gel treatment group had an average specific tension of 76.63 ± 
15.26%, which was not a significant improvement compared to the no treatment group. 
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Day 14 measurements showed significant improvement in specific tension (p<0.05) for 
MSCs + PEGylated fibrin gel (91.26 ± 4.06%) compared to no treatment (67.11 ± 
9.40%). MSC and PEGylated fibrin gel treatment groups did not have significant 
improvements in force production, with specific tension values of 71.74 ± 9.21% and 
68.12 ± 6.23%, respectively. We hypothesize that the MSC + PEGylated fibrin gel group 
led to significant improvements in force production because the MSCs are contributing to 
functional recovery and restoration of the ischemic tissue. However, the PEGylated fibrin 
gel microenvironment appears to modulate the MSCs, as the MSC only treatment group 
did not have significant improvements in force production at day 14. The gel assists in 
retaining the MSCs at the delivery site, allowing the cells to contribute to skeletal muscle 
regeneration either through differentiation or paracrine effects. In addition, the gel could 
be acting as a depot to collect cytokines and growth factors, either released endogenously 
or from the delivered MSCs. This in turn could impart autocrine and paracrine effects on 
the MSCs and surrounding cells. Also, the hypoxic microenvironment of the ischemic 
tissue and the PEGylated fibrin gel could be modulating stem cell function, as outlined in 
Chapter 5. In particular, the interaction of MSCs with infiltrating macrophages could 
modulate macrophage function, inducing changes in macrophage phenotype necessary 
for skeletal muscle regeneration.
26-29
 
Interestingly, although the ischemia model investigated here did not appear to 
result in any damage when evaluated histologically (such as cell infiltration and 
necrosis), functional deficits still occurred. Others have seen functional deficits in hind 
limb ischemia models using femoral artery ligation with no corresponding histological 
evidence of inflammatory cell infiltration, fibrosis, or edema.
18,30-32
 The results presented 
here are in agreement with these other studies, in which consistent, moderate ischemia is 
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associated with less severe inflammation and necrosis compared to acute, severe 
ischemia.
18,30-32
 
6.4 CONCLUSIONS 
This study investigated the use of mesenchymal stem cell therapy for ischemic 
injury. MSCs delivered within a PEGylated fibrin gel contributed to significant 
improvements in blood vessel formation and blood flow, as well as functional recovery of 
the ischemic limb, on day 14. None of the other treatment groups (MSCs or PEGylated 
fibrin gel) exhibited such significant improvements. Thus, the results demonstrate that 
MSCs delivered in combination with PEGylated fibrin gel is a promising therapy for 
treatment of ischemic diseases. This therapeutic mechanism could be attributed to the 
stem cells themselves, which secrete pro-angiogenic factors and recruit other cell types 
for wound healing, as well as the gel microenvironment. The recruitment and interaction 
with macrophages could also potentially be a contributing factor, as macrophages have 
been found to participate in angiogenesis and wound healing and to accumulate around 
growing collaterals.
33-35
 Not only will the gel alter the microenvironment for the 
delivered stem cells, but it also acts as a depot for released cytokines and growth factors 
and is a natural component of the wound healing response.  
While this model of hind limb ischemia did not result in tissue necrosis, as 
assessed histologically, functional deficits still occurred. It has been demonstrated that 
the severity of ischemic injury, and the extent of arteriogenesis, is dependent upon the 
species and strain of the animal used.
17,36
 Thus, future studies could implement a more 
severe ischemia model, potentially using a disease animal model which is more 
representative of the patient population suffering from peripheral artery disease. 
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Figure 6.1: Schematic illustrating the sites of ligation immediately distal to the inferior 
epigastric artery and proximal to the branch point of the popliteal and 
saphenous arteries. 
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Figure 6.2: In vitro MSC viability following injection within a PEGylated fibrin gel. 
Scale bar = 100 µm. 
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Figure 6.3: (A) Smooth muscle actin (SMA) staining of ischemic muscles with various 
treatments, and contralateral control, at day 7 and 14. Quantification of (B) 
SMA positive area and (C) the number of SMA positive vessels.  (* = 
p<0.05 compared to no treatment) 
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Figure 6.4: Evaluation of blood flow to ischemic hind limbs using thermal infrared 
imaging. (* = p<0.05 compared to no treatment) 
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Figure 6.5: MSC localization and distribution within the muscle following injection 
for MSC and MSC + PEGylated fibrin gel groups on days 7 and 14. MSCs 
are shown in red (CM-DiI) and cell nuclei are shown in blue (DAPI). Scale 
bar = 100 µm. 
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Figure 6.6: Hematoxylin and eosin staining of ischemic muscles with various 
treatments, and contralateral control, at day 7 and 14. Scale bar = 100 µm. 
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Figure 6.7: Maximum force production measurements of the lateral gastrocnemius 7 
and 14 days following treatment. Black lines indicate mean values for each 
treatment group. (* = p<0.05 compared to no treatment) 
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Chapter 7: Conclusions and future work 
7.1 SUMMARY OF PRESENT FINDINGS AND CONCLUSIONS 
Cardiovascular diseases are the leading cause of death globally,
1
 and the mortality 
rate is expected to continue to rise over the next 30 years
2,3
. Despite advances in 
revascularization procedures, many patients do not respond well to currently available 
treatments, or are not even eligible for these therapies, due partially to co-morbidities.
4
 
However, cell-based therapies have been shown to be a promising alternative, with 
preclinical and clinical trials using bone marrow-derived mesenchymal stem cells 
demonstrating improved outcomes.
5
 Furthermore, incorporating biomaterial delivery 
systems can be beneficial for cell-based therapies by increasing the rate of cell retention 
and altering cell function to promote healing. 
The objective of this thesis was to evaluate the use of bone marrow-derived 
mesenchymal stem cells delivered within a PEGylated fibrin gel biomatrix for 
revascularization therapies. This evaluation included designing nanoparticle contrast 
agents for tracking stem cells in vivo using noninvasive imaging techniques; assessing the 
influence of hypoxia on MSCs and the resulting interactions with endogenous cell types; 
and  demonstrating the extent of neovascularization and functional recovery within a hind 
limb ischemia model. Specifically, Chapters 2 and 3 investigated the potential application 
of nanoparticle contrast agents for stem cell monitoring. Chapter 2 demonstrated that 
gold nanoparticles of various sizes and surface coatings are safe labeling agents for stem 
cells, as cell function and viability were not affected. Chapter 3 attempted to explore the 
development of a nanoparticle system which would dissociate within endosomal 
compartments with minimal biologic effects and not accumulate in subsequent cell 
populations or in organs in vivo. This system consisted of 5 nm nanoparticles which were 
aggregated using a poly-L-lysine coating to promote cellular uptake. However, this 
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nanoparticle system proved to not be ideal, as the nanoparticles were found to be 
transferred to macrophages. As a result, this prompted further investigation into a 
nanoparticle system which also monitored infiltration of macrophages, both to detect the 
transfer of contrast agents from MSCs to non-stem cells, as well as to potentially evaluate 
the therapeutic contribution of macrophages to wound healing. This dual nanoparticle 
system is outlined in Chapter 4. This nanoparticle system was safe in terms of 
maintaining cell viability and function. In addition, the system preferentially labeled the 
cells of interest (either macrophages or MSCs), allowing the distinction between the two 
cell types using photoacoustic imaging (both in vitro and in vivo). Histological analysis 
and cell sorting confirmed the labeling of macrophages with nanoparticles within a hind 
limb ischemia model.  
The motivation for monitoring macrophage infiltration was two-fold: to help 
distinguish the transfer of contrast agents to non-stem cells and also to evaluate the 
infiltration of macrophages following injury as part of the wound healing response. 
Macrophages have been shown to have important functions in tissue repair, including 
skeletal muscle, cardiac muscle, and vascular regeneration. Chapter 5 evaluated the 
interaction between MSCs and macrophages, specifically in relation to an in vivo 
ischemic injury environment. MSCs naturally reside within a hypoxic environment and 
have been shown to produce improved angiogenic responses following an ischemic 
injury.
6-10
 Chapter 5 demonstrated influence of an in vitro hypoxic environment on MSCs 
and found MSCs undergo a stress response to mild (2%) or severe (1%) hypoxia. 
Specifically, MSCs exhibited increased cell proliferation and upregulation of pro-
angiogenic and anti-apoptotic factors. In addition, the role of macrophages in wound 
healing and angiogenesis was evaluated, with emphasis on the interaction between MSCs 
and macrophages. It was found that culturing macrophages with MSC conditioned media 
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did not have immunomodulatory effects. However, co-culturing MSCs and macrophages 
led to changes in both cell types, including soluble factor secretion and phenotypic 
changes.  
Finally, the therapeutic effects of MSCs delivered within a PEGylated fibrin gel 
were evaluated using a hind limb ischemia model. While the PEGylated fibrin gel itself 
seemed to impart some angiogenic effects, delivering MSCs in combination a PEGylated 
fibrin gel were found to enhance vascular formation, perfusion of the ischemic limb, and 
functional recovery of the tissue. 
7.2 FUTURE DIRECTIONS 
This thesis focused on demonstrating the feasibility of labeling MSCs with gold 
nanoparticles for cell tracking. However, one of the drawbacks of using gold 
nanoparticles as cell tracking agents is the inability to distinguish viable from nonviable 
cells. While the dual nanoparticle system presented in this thesis partially addressed this 
issue, the system is not able to definitively determine if the MSCs are viable, but instead 
only if macrophages infiltrated the area and endocytosed the MSCs. Thus, a major 
contribution to the field would be to design a gold nanoparticle contrast agent which is 
capable of monitoring MSCs noninvasively using photoacoustic imaging and also 
determine if the cells are viable or changing function (e.g. differentiating to another cell 
type). Such a system could involve a caspase-degradable nanoparticle system which is 
activated following cell death, leading to changes in the optical absorption characteristics 
of the particles, and thus the photoacoustic signal. 
Investigation of silica coated gold nanorods revealed that the silica coating is no 
longer present on the nanorod surface following cellular endocytosis. Further 
investigation is needed to elucidate the mechanisms responsible for the degradation of the 
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silica layer, including the time course of the degradation process. Possible mechanisms 
for the silica degradation could be penetration of serum proteins into the porous silica 
coating or the intracellular environment (including pH and hydrolytic enzymes). 
Obtaining a better understanding of the degradation mechanisms could also contribute to 
the design of a multimodal system, in which drugs/genes are loaded into the silica layer 
and released at the site of interest as a result of silica degradation. The gold nanoparticles 
would serve as an imaging contrast agent for monitoring purposes. 
The interaction between MSCs and other cell types, specifically macrophages, is 
essential for wound healing to occur. This work demonstrated that MSCs are responsive 
to a hypoxic environment, with the expression of more pro-regenerative characteristics. 
In addition, this work also showed that macrophages are influenced by MSCs, especially 
when the interaction between the two cell types occurs within a hypoxic environment. 
However, more extensive studies on the interaction between MSCs and macrophages can 
be conducted. For example, in order to more precisely characterize macrophage 
phenotype along the M1/M2 spectrum, additional markers for M1 (e.g. CXCL9/10/11/19 
and indoleamine-pyrrole 2,3 dioxygenase (IDO)) and M2 (e.g. CCL13/18, prostaglandin 
E2 (PGE2), and insulin-like growth factor 1 (IGF-1)) should be analyzed. Other analysis 
techniques could also be incorporated for phenotype classification, such as intracellular 
staining and fluorescence-activated cell sorting. Also, this work focused on the 
interaction between MSCs and macrophages within a 2D environment. However, in order 
to more closely resemble the in vivo scenario, it would be beneficial to study the 
interaction between the cell types within a 3D environment, such as the PEGylated fibrin 
gels. Also, translating these studies to an in vivo situation would be beneficial, such as 
evaluating the changes in macrophage phenotype within the ischemic tissue treated with 
MSCs in combination with PEGylated fibrin gel. 
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Lastly, more accurate models of peripheral artery disease are necessary to test the 
effectiveness of stem cell therapy in humans. The work presented here used a femoral 
artery ligation to induce hind limb ischemia in a rodent model. However, the extensive 
collateral network within the rat hind limb, and the lack of exercise following the injury, 
limited the damage to the tissue. In addition, this is an acute model of ischemia, which is 
not necessarily representative of the gradual onset of peripheral artery disease which 
occurs in humans.  Also, many patients with peripheral artery disease have existing co-
morbidities, such as diabetes, and thus the use of a diseased animal model would be a 
more relevant model. Finally, many patients have to undergo multiple revascularization 
procedures because of restenosis or reclotting of the vessel. However, revascularization 
induces reperfusion injury. Thus a more clinically relevant model may be a patient who 
has had an acute ischemic event and is postoperative to a revascularization procedure. 
Taken together, a more optimal animal model would involve a diseased rodent model 
which has undergone gradual onset of ischemia and experienced a reperfusion event. 
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